Differences, similarities, and which is better for you

Drug overview & main differences | Conditions treated | Efficacy | Insurance coverage and cost comparison | Side effects | Drug interactions | Warnings | FAQ

You may be recommended a nonsteroidal anti-inflammatory drug (NSAID) like meloxicam or ibuprofen for pain and inflammation. These drugs decrease the production of prostaglandins, which are substances responsible for pain, fever, and inflammation in the body. Although meloxicam and ibuprofen work in similar ways, they have some differences.

Both meloxicam and ibuprofen are considered nonselective NSAIDs. This means that they both block the COX-1 and COX-2 enzymes. These cyclooxygenase enzymes are responsible for prostaglandin production. However, COX-1 enzyme is also associated with protective effects in the stomach.

What are the main differences between meloxicam vs. ibuprofen?

Meloxicam is a generic medication that can only be taken with a prescription from a doctor. Meloxicam is sometimes known by its brand name, Mobic. It can be used to treat different forms of arthritis in adults and children aged 2 years and older. Meloxicam is usually administered as a once-daily pill.

Ibuprofen is a common over-the-counter (OTC) medication that is used for pain, inflammation, and fever in adults and children aged 6 months and older. Brand names for ibuprofen include Advil, Motrin, and Midol. Ibuprofen can also be prescribed as a higher dose to treat arthritis. Prescription-strength ibuprofen is usually taken every 6 to 8 hours for pain relief.

Main differences between meloxicam and ibuprofen
Drug class	Nonsteroidal anti-inflammatory drugs (NSAID)	Nonsteroidal anti-inflammatory drugs (NSAID)
Brand/generic status	Generic available	Generic available
What is the brand name?	Mobic	Advil, Motrin, Midol
What form(s) does the drug come in?	Oral tablet Liquid suspension	Oral tablet Oral capsule Liquid suspension
What is the standard dosage?	7. 5 mg daily	400 to 800 mg every six to eight hours
How long is the typical treatment?	Example: 7-14 days	Not longer than 10 days or as instructed by your doctor
Who typically uses the medication?	Adults and children aged 2 years and older	Adults and children aged 6 months and older

Want the best price on ibuprofen?

Sign up for ibuprofen price alerts and find out when the price changes!

Get price alerts

Conditions treated by meloxicam vs. ibuprofen

Pain from arthritis is caused by inflammation in the joints. NSAIDs are often used to treat mild to moderate pain that is also chronic in nature. Meloxicam is FDA-approved to treat the most common form of arthritis—osteoarthritis, which affects millions of people each year. Meloxicam is also indicated to treat rheumatoid arthritis in both adults and children (juvenile rheumatoid arthritis) aged 2 years and older. Off-label uses of meloxicam include pain from menstrual cramps (dysmenorrhea), general pain, and fever.

Like other NSAIDs, ibuprofen is approved to treat osteoarthritis, rheumatoid arthritis, and juvenile arthritis. It is safe and effective for adults and children aged 6 months and older. Ibuprofen can also treat dysmenorrhea, fever, and pain from muscle aches and migraines.

NSAIDs should be taken with the medical advice of a healthcare professional. Consult a doctor if you experience any of the following conditions.

Is meloxicam or ibuprofen more effective?

Head-to-head trials have not yet been performed with meloxicam and ibuprofen for arthritis. However, meloxicam and ibuprofen were compared in one trial for their effectiveness in dental pain. Meloxicam, ibuprofen, and acetaminophen were given to trial subjects 1 hour before separator placement. No significant differences in effectiveness were found between the drugs. Ultimately, the study concluded that meloxicam was effective with less gastric side effects.

One meta-analysis compared several NSAIDs, including meloxicam, ibuprofen, naproxen, diclofenac, nabumetone, and oxaprozin for arthritic pain. The study found that the NSAIDs were comparable in effectiveness.

While effectiveness is comparable for NSAIDs, someone might prefer using one based on other factors such as its potential for side effects, price, and dosing. Because meloxicam is dosed once daily and can only be taken with a prescription, it may be more potent than ibuprofen. OTC ibuprofen is not as effective as prescription-strength ibuprofen for moderate pain.

Want the best price on meloxicam?

Sign up for meloxicam price alerts and find out when the price changes!

Get price alerts

Coverage and cost comparison of meloxicam vs.

ibuprofen

Meloxicam is covered by most Medicare and insurance plans. As a generic prescription drug, meloxicam can be purchased for an average retail cost of $31.99. When you purchase meloxicam from a pharmacy, you can use a SingleCare discount card to lower the cost to as low as $8.99 for a 30 days supply of 7.5 mg tablets. The actual reduced price may depend on which pharmacy you go to.

Prescription-strength ibuprofen is often covered by insurance plans. However, lower dose OTC ibuprofen is usually not covered because it does not need a prescription. Ibuprofen can cost an average retail price of $14.99. Using a SingleCare coupon can reduce the cost to $3.00 at most pharmacies that take SingleCare discount cards or coupons.

Common side effects of meloxicam vs.

ibuprofen

Meloxicam and ibuprofen share many of the same side effects. Like most NSAIDs, meloxicam and ibuprofen can have gastrointestinal side effects such as stomach upset, indigestion, diarrhea, nausea, and gas (flatulence). Common side effects of these NSAIDs also include headaches, dizziness, rash, and edema (swelling of the hands and/or feet).

In addition, side effects of meloxicam include flu-like symptoms and sore throat (pharyngitis). Because meloxicam is partially COX-2 selective, it may have fewer serious gastrointestinal effects.

Serious adverse effects of meloxicam and ibuprofen can include cardiovascular events like heart attack or stroke as well as gastrointestinal events like stomach ulcers and bleeding. Consult your healthcare provider if you experience any serious side effects from these medications.

This may not be a complete list. Consult your doctor or pharmacist for possible side effects.
Source: DailyMed (Meloxicam), DailyMed (Ibuprofen)

Drug interactions of meloxicam vs. ibuprofen

Meloxicam and ibuprofen can interact with drugs that affect homeostasis. These drugs can include anticoagulants, antiplatelets, SSRI drugs, and SNRI drugs. Taking NSAIDs with these drugs may increase the risk of bleeding. Meloxicam and ibuprofen should be avoided with another aspirin, which is an NSAID that also acts as an antiplatelet medication for blood clots.

Meloxicam and ibuprofen can also interact with medications that treat high blood pressure. Taking NSAIDs may decrease the effects of high blood pressure medications like ACE inhibitors, ARBs, diuretics, and beta blockers. NSAIDs and blood pressure medications can also interact and cause kidney problems.

Those who take lithium or methotrexate may be at a higher risk of toxicity if they are also taking NSAIDs. This is because NSAIDs can affect how these drugs are processed in the body which can lead to toxic levels in the body.

This may not be a complete list of all possible drug interactions. Consult a doctor with all medications you may be taking.

Warnings of meloxicam vs. ibuprofen

Both meloxicam and ibuprofen can increase the risk of heart attacks and strokes. This is because NSAIDs can alter the blood clotting functions of the body and harden the arteries over time. Cardiovascular events are not likely to occur during a short period of treatment. Those with a history of heart disease may be at a higher risk of these events.

Meloxicam and ibuprofen can also increase blood pressure. They should be monitored when taken with other blood pressure medications. Meloxicam and ibuprofen should not be used in those with risk factors such as a history of coronary artery bypass graft (CABG) surgery.

Meloxicam and ibuprofen can cause an increased risk of gastrointestinal adverse effects such as stomach ulcers and bleeding. They should be avoided in the elderly and anyone who has had a history of peptic ulcer disease and bleeding in the stomach or intestines.

Meloxicam and ibuprofen may cause toxicity in the liver and kidneys. Toxicity can occur with higher doses over time. Kidney problems can also play a role in worsening heart failure.

NSAIDs should be avoided in later pregnancy. This is because they can prematurely close the ductus arteriosus, which is an important blood vessel in the fetal heart. Caution should be taken with NSAIDs during pregnancy.

Frequently asked questions about meloxicam vs. ibuprofen

What is meloxicam?

Meloxicam is a prescription NSAID that is used to treat osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis. The brand name for meloxicam is Mobic. It is usually prescribed as 7.5 mg once daily adults and children with a weight equal to or greater than 60 kg.

What is ibuprofen?

Ibuprofen is an NSAID that is available over-the-counter for pain and fever. It is also available in higher prescription-strength doses to treat moderate pain from arthritis. Ibuprofen is often taken every 6 to 8 hours to treat pain or fever in adults and children aged 6 months and older.

Are meloxicam vs. ibuprofen the same?

Meloxicam and ibuprofen are not the same. Meloxicam is a once-daily medication that can only be used with a prescription. Ibuprofen needs to be taken in higher doses to be effective for higher pain levels.

Is meloxicam or ibuprofen better?

Meloxicam and ibuprofen are both effective for pain. They have both been shown to be comparable NSAIDs depending on the type of pain being treated. For some people, meloxicam may be preferred for its once-daily dosing.

Can I use meloxicam or ibuprofen while pregnant?

Like other NSAIDs, meloxicam and ibuprofen should be avoided after 30 weeks of gestation. This is because they can cause problems in the fetal heart. If you are pregnant, it’s important to discuss the use of NSAIDs with a doctor.

Can I use meloxicam and ibuprofen with alcohol?

It is not recommended to drink alcohol while taking NSAIDs like meloxicam and ibuprofen. Alcohol can act as a blood thinner and increase the risk of bleeding with NSAIDs.

Does meloxicam make you sleepy?

Sleepiness is not a common side effect of meloxicam. However, overdosing on meloxicam may cause some sleepiness. In this case, you may need to seek immediate medical attention. The most common side effects of meloxicam include abdominal pain, nausea, dizziness, and headache.

Is meloxicam a strong painkiller?

Meloxicam is a potent painkiller for arthritis. It is FDA approved to treat pain and inflammation from osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis. As a once-daily medication, it is a strong NSAID.

Mobic (Meloxicam) Drug / Medicine Information

Tablets and Capsules

Meloxicam

Consumer Medicine Information

What is in this leaflet

This leaflet answers some common questions about Mobic.

It does not contain all the available information.

It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you taking
Mobic against the benefits they expect it will have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

This leaflet was last updated on the date at the end of this leaflet. More recent
information may be available. The latest Consumer Medicine Information is available
from your pharmacist, doctor, or from www.medicines.org.au and may contain important
information about the medicine and its use of which you should be aware.

Keep this leaflet with the medicine.

You may need to read it again.

What Mobic is used for

Mobic is used to treat the symptoms of:

osteoarthritis

rheumatoid arthritis.

Both diseases mainly affect the joints causing pain and swelling.

Although Mobic can relieve the symptoms of pain and inflammation, it will not cure
your condition. Mobic belongs to a family of medicines called Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs). These medicines work by relieving pain and inflammation.

Ask your doctor if you have any questions about why this medicine has been prescribed
for you.

Your doctor may have prescribed it for another reason.

This medicine is available only with a doctor’s prescription.

Before you take Mobic

When you must not take it

Do not take Mobic if you have an allergy to:

any medicine containing meloxicam

any of the ingredients listed at the end of this leaflet

aspirin or any other NSAIDs.

Some of the symptoms of an allergic reaction may include:

shortness of breath

wheezing or difficulty breathing

swelling of the face, lips, tongue or other parts of the body

rash, itching or hives on the skin.

Do not take Mobic if you:

are about to undergo a coronary artery bypass graft surgery

have a disease of the heart with shortness of breath, and swelling of the feet or
lips due to fluid build-up

experience bleeding from the stomach, gut or any other bleeding

had a stroke resulting from a bleed in the brain or have a bleeding disorder

have a galactose intolerance

have a peptic (stomach) ulcer

have or have had inflammation of the lining of the stomach or bowel (e.g. Crohn’s
Disease or Ulcerative Colitis)

have severe liver or kidney problems

are currently taking the following medicines: fluconazole (used to treat fungal infections)
or certain sulfur antibiotics (e. g. sulfamethoxazole).

Do not breast-feed if you are taking this medicine.

The active ingredient in Mobic passes into breast milk and there is a possibility
that your baby may be affected.

Do not give this medicine to a child under the age of 18 years.

Safety and effectiveness in children younger than 18 years have not been established.

Do not take this medicine after the expiry date printed on the pack or if the packaging
is torn or shows signs of tampering.

If it has expired or is damaged, return it to your pharmacist for disposal.

If you are not sure whether you should start taking this medicine, talk to your doctor.

Before you start to take it

Tell your doctor if you have allergies to any other medicines, food, preservative
or dyes.

Tell your doctor if you have or have had any of the following medical conditions:

high blood pressure or fluid retention

diabetes

high cholesterol

heartburn, indigestion, ulcers or other stomach problems

kidney or liver disease

asthma or any other breathing problems.

Tell your doctor if you are pregnant or intend to become pregnant.

Like most NSAID medicines, Mobic is not recommended for use during pregnancy. If there
is a need to consider Mobic during your pregnancy, your doctor will discuss with you
the benefits and risks of using it.

Tell your doctor if you are using an IUD (intrauterine device) for birth control.

NSAID medicines, like Mobic, may decrease the effectiveness of IUDs.

Tell your doctor if you currently have an infection.

Mobic may hide some of the signs of an infection. This may make you think, mistakenly,
that you are better or that it is not serious.

If you have not told your doctor or pharmacist about any of the above, tell them before
you start taking Mobic.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any
that you get without a prescription from your pharmacy, supermarket or health food
shop.

Some medicines and Mobic may interfere with each other. These include:

aspirin, salicylates or other NSAIDs

medicines used to thin your blood (e.g. warfarin, heparin and ticlopidine)

medicines used to treat high blood pressure and other heart problems (e.g. ACE inhibitors,
angiotensin receptor antagonists and diuretics, also called fluid or water tablets)

When taken together these medicines can cause kidney problems.

lithium, a medicine used to treat some types of depression

antidepressants called selective serotonin reuptake inhibitors (SSRIs)

methotrexate, a medicine used to treat rheumatoid arthritis and some types of cancer

ciclosporin, a medicine used to treat rheumatoid arthritis and certain problems with
the immune system

terfenadine and astemizole, medicines used to prevent or relieve the symptoms of allergy,
such as hay fever or insect stings

medicines to treat diabetes

colestyramine, a medicine used to treat high cholesterol levels in the blood

corticosteroids, medicines usually used to treat inflammatory conditions, such as
skin rashes and asthma

some medicines used to treat infections (e.g. erythromycin, sulfur antibiotics, ketoconazole,
itraconazole)

some medicines used to treat irregular heartbeats (e. g. amiodarone and quinidine)

pemetrexed, a medicine used in the treatment of certain lung cancers.

These medicines may be affected by Mobic or may affect how well it works. You may
need different amounts of your medicines, or you may need different medicines.

Your doctor and pharmacist have more information on medicines to be careful with or
avoid while taking this medicine.

How to take Mobic

Follow all directions given to you by your doctor or pharmacist carefully.

They may differ from the information contained in this leaflet.

How much to take

For the treatment of osteoarthritis

The usual dose of Mobic is 7.5 mg, taken as a single dose each day.

Depending on the severity of your condition and your response to treatment, your doctor
may increase this dose to 15 mg taken as a single dose each day.

For the treatment of rheumatoid arthritis

The usual dose of Mobic is 15 mg taken as a single dose each day.

Depending on your response, your doctor may reduce this dose to 7.5 mg taken as a
single dose each day.

The maximum recommended daily dose of Mobic is 15 mg.

For patients with kidney problems undergoing dialysis, the maximum recommended daily
dose is 7.5 mg.

Ask your doctor for more information if you have been advised to take a different
dose.

How to take it

Swallow the tablets or capsules whole with a full glass of water.

When to take it

Take your medicine at about the same time each day.

Taking it at the same time each day will have the best effect. It will also help you
remember when to take it.

Take your medicine with or straight after food.

This may help reduce the possibility of stomach upset.

How long to take it

Continue taking your medicine for as long as your doctor tells you.

This medicine helps control your condition, but does not cure it. It is important
to keep taking your medicine even if you feel well.

If you forget to take it

If it is almost time for your next dose (e.g. within 2-3 hours), skip the dose you
missed and take the next dose when you are meant to.

Otherwise, take it as soon as you remember, then go back to taking it as you would
normally.

Do not take a double dose to make up for the dose that you missed.

If you are not sure what to do, ask your doctor or pharmacist.

If you have trouble remembering to take your medicine, ask your pharmacist for some
hints.

If you take too much (overdose)

Immediately telephone your doctor or Poisons Information Centre (telephone 13 11 26)
for advice, or go to Emergency at your nearest hospital if you think that you or anyone
else may have taken too much Mobic. Do this even if there are no signs of discomfort
or poisoning.

You may need urgent medical attention.

Symptoms of an overdose may include:

nausea and/or vomiting

headache

drowsiness and/or dizziness

blurred vision

fits or seizures

low blood pressure

difficulty in breathing

impaired consciousness

kidney failure.

While you are using Mobic

Things you must do

If you are about to be started on any new medicine, remind your doctor and pharmacist
that you are taking Mobic.

Tell any other doctors, dentists, and pharmacists who treat you that you are taking
this medicine.

If you are going to have surgery, tell the surgeon or anaesthetist that you are taking
Mobic.

Mobic can slow down blood clotting.

If you become pregnant while taking this medicine, tell your doctor immediately.

If you get an infection while using Mobic, tell your doctor.

Mobic may hide some of the signs of an infection (e.g. pain, fever, redness and swelling).
You may think, mistakenly, that you are better or that the infection is not serious.

Things you must not do

Do not take Mobic to treat any other complaints unless your doctor tells you to.

Do not give your medicine to anyone else, even if they have the same condition as
you.

Do not stop taking your medicine or lower the dosage without checking with your doctor.

Things to be careful of

Be careful driving or operating machinery until you know how Mobic affects you.

This medicine may cause dizziness, drowsiness or blurred vision in some people. If
you have any of these symptoms, do not drive, operate machinery or do anything else
that could be dangerous.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you
are taking Mobic.

This medicine helps most people but it may have unwanted side effects in a few people.
All medicines have side effects. Sometimes they are serious, most of the time they
are not. You may need medical attention if you get some of the side effects.

Do not be alarmed by the following lists of side effects. You may not experience any
of them.

Not all of these side effects have been reported with Mobic but have been seen with
similar medicines.

Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor or pharmacist if you notice any of the following and they worry you:

stomach upset including: nausea, vomiting, heartburn, indigestion, belching, cramps
or pain

headache

flu-like symptoms, runny or blocked nose, cough, sore mouth or throat, discomfort
when swallowing

constipation, diarrhoea or wind

dizziness or light-headedness

skin rashes, which may be caused by exposure to sunlight, can blister and may take
on the appearance of a severe burn, or itching

increase in blood pressure

tinnitus (ringing in the ear).

The above list includes the more common side effects of your medicine. These side
effects are usually mild.

Tell your doctor immediately if you notice any of the following:

blurred vision

any change in the amount or colour of your urine (red or brown) or any pain or difficulty
experienced when urinating

collapse or fainting, shortness of breath or tiredness, fast or irregular heartbeat,
chest pain, swollen or sore leg veins

severe dizziness

severe pain or tenderness in the stomach

flaking of the skin

yellowing of the skin and eyes (known as jaundice)

swelling of your ankles, legs or other parts of your body

signs of anaemia (such as: tiredness, being short of breath and looking pale)

irritation of your mucous membranes (e. g. lips, mouth, eyes or genitals).

These are rare but serious side effects. You may need urgent medical attention.

If any of the following happen, tell your doctor immediately or go to Emergency at
your nearest hospital:

vomiting of blood or material that looks like coffee grounds

bleeding from your back passage (rectum), black sticky motions (stools) or bloody
diarrhoea

swelling of the face, lips or tongue which may make swallowing or breathing difficult

asthma, wheezing or shortness of breath

sudden or severe itching, skin rash or hives

weakness in one part or side of your body, slurred speech, blurred vision or visual
disturbances.

These are rare but very serious side effects. You may need urgent medical attention
or hospitalisation.

Tell your doctor or pharmacist if you notice anything else that is making you feel
unwell.

Other side effects not listed above may occur in some people.

After using Mobic

Storage

Keep your tablets or capsules in their pack until it is time to take them.

If you take them out of the pack they may not keep well.

Keep your tablets or capsules in a cool dry place where the temperature stays below
25°C.

Do not store Mobic or any other medicine in the bathroom or near a sink. Do not leave
it on a window sill or in the car.

Heat and dampness can destroy some medicines.

Keep it where children cannot reach it.

A locked cupboard at least one-and-a-half metres above the ground is a good place
to store medicines.

Disposal

If your doctor tells you to stop taking this medicine or the expiry date has passed,
ask your pharmacist what to do with any medicine that is left over.

Product description

What it looks like

Mobic is the brand name of your medicine. It is available as tablets or capsules in
two strengths.

Mobic 7.5 mg tablets – pastel-yellow, round tablets, marked 59D on one side with break
bar, and company logo on the other.

Available in blister packs of 10*, 20*, 30, 60* and 100* tablets.

Mobic 15 mg tablets – pastel-yellow, round tablets, marked 77C on one side with break
bar, and company logo on the other.

Available in blister packs of 10*, 20*, 30, 60* and 100* tablets.

Mobic 7.5 mg capsules – pale green capsules.

Available in blister packs of 10*, 20*, 30 and 100* capsules.

Mobic 15 mg capsules – pale yellow/pale green capsules.

Available in blister packs of 10*, 20*, 30 and 100* capsules.

*Not distributed in Australia.

Ingredients

Active ingredient:

Mobic 7.5 mg tablet or capsule – 7.5 mg of meloxicam.

Mobic 15 mg tablet or capsule – 15 mg of meloxicam.

Inactive ingredients:

Mobic tablets also contain:

sodium citrate dihydrate

lactose monohydrate

microcrystalline cellulose

povidone

crospovidone

colloidal anhydrous silica

magnesium stearate.

Mobic capsules also contain:

sodium citrate dihydrate

lactose monohydrate

maize starch

magnesium stearate

gelatin

indigo carmine CI73015

iron oxide yellow CI77492

titanium dioxide

purified water.

Mobic does not contain gluten or sucrose.

Supplier

Mobic is supplied in Australia by:

BOEHRINGER INGELHEIM PTY LIMITED

ABN 52 000 452 308

78 Waterloo Road

North Ryde NSW 2113

This leaflet was revised in May 2017

® Mobic is a registered trademark of Boehringer Ingelheim.

© Boehringer Ingelheim Pty Limited 2017.

Australian Registration Number(s)

Mobic 7.5 mg tablets:

AUST R 77694.

Mobic 15 mg tablets:

AUST R 77695.

Mobic 7.5 mg capsules:

AUST R 77698.

Mobic 15 mg capsules:

AUST R 77699.

Mobic Capsules – NPS MedicineWise

What is in this leaflet

This leaflet answers some common questions about Mobic.

It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you taking Mobic against the benefits they expect it will have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

This leaflet was last updated on the date at the end of this leaflet. More recent information may be available. The latest Consumer Medicine Information is available from your pharmacist, doctor, or from www.medicines.org.au and may contain important information about the medicine and its use of which you should be aware.

Keep this leaflet with the medicine.

You may need to read it again.

What Mobic is used for

Mobic is used to treat the symptoms of:

• osteoarthritis
• rheumatoid arthritis.

Both diseases mainly affect the joints causing pain and swelling.

Although Mobic can relieve the symptoms of pain and inflammation, it will not cure your condition. Mobic belongs to a family of medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). These medicines work by relieving pain and inflammation.

Ask your doctor if you have any questions about why this medicine has been prescribed for you.

Your doctor may have prescribed it for another reason.

This medicine is available only with a doctor’s prescription.

Before you take Mobic

When you must not take it

Do not take Mobic if you have an allergy to:

• any medicine containing meloxicam
• any of the ingredients listed at the end of this leaflet
• aspirin or any other NSAIDs.

Some of the symptoms of an allergic reaction may include:

• shortness of breath
• wheezing or difficulty breathing
• swelling of the face, lips, tongue or other parts of the body
• rash, itching or hives on the skin.

Do not take Mobic if you:

• are about to undergo a coronary artery bypass graft surgery
• have a disease of the heart with shortness of breath, and swelling of the feet or lips due to fluid build-up
• experience bleeding from the stomach, gut or any other bleeding
• had a stroke resulting from a bleed in the brain or have a bleeding disorder
• have a galactose intolerance
• have a peptic (stomach) ulcer
• have or have had inflammation of the lining of the stomach or bowel (e.g. Crohn’s Disease or Ulcerative Colitis)
• have severe liver or kidney problems
• are currently taking the following medicines: fluconazole (used to treat fungal infections) or certain sulfur antibiotics (e.g. sulfamethoxazole).

Do not breast-feed if you are taking this medicine.

The active ingredient in Mobic passes into breast milk and there is a possibility that your baby may be affected.

Do not give this medicine to a child under the age of 18 years.

Safety and effectiveness in children younger than 18 years have not been established.

Do not take this medicine after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering.

If it has expired or is damaged, return it to your pharmacist for disposal.

If you are not sure whether you should start taking this medicine, talk to your doctor.

Before you start to take it

Tell your doctor if you have allergies to any other medicines, food, preservative or dyes.

Tell your doctor if you have or have had any of the following medical conditions:

• high blood pressure or fluid retention
• diabetes
• high cholesterol
• heartburn, indigestion, ulcers or other stomach problems
• kidney or liver disease
• asthma or any other breathing problems.

Tell your doctor if you are pregnant or intend to become pregnant.

Like most NSAID medicines, Mobic is not recommended for use during pregnancy. If there is a need to consider Mobic during your pregnancy, your doctor will discuss with you the benefits and risks of using it.

Tell your doctor if you are using an IUD (intrauterine device) for birth control.

NSAID medicines, like Mobic, may decrease the effectiveness of IUDs.

Tell your doctor if you currently have an infection.

Mobic may hide some of the signs of an infection. This may make you think, mistakenly, that you are better or that it is not serious.

If you have not told your doctor or pharmacist about any of the above, tell them before you start taking Mobic.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop.

Some medicines and Mobic may interfere with each other. These include:

• aspirin, salicylates or other NSAIDs
• medicines used to thin your blood (e.g. warfarin, heparin and ticlopidine)
• medicines used to treat high blood pressure and other heart problems (e.g. ACE inhibitors, angiotensin receptor antagonists and diuretics, also called fluid or water tablets)

When taken together these medicines can cause kidney problems.

• lithium, a medicine used to treat some types of depression
• antidepressants called selective serotonin reuptake inhibitors (SSRIs)
• methotrexate, a medicine used to treat rheumatoid arthritis and some types of cancer
• ciclosporin, a medicine used to treat rheumatoid arthritis and certain problems with the immune system
• terfenadine and astemizole, medicines used to prevent or relieve the symptoms of allergy, such as hay fever or insect stings
• medicines to treat diabetes
• colestyramine, a medicine used to treat high cholesterol levels in the blood
• corticosteroids, medicines usually used to treat inflammatory conditions, such as skin rashes and asthma
• some medicines used to treat infections (e. g. erythromycin, sulfur antibiotics, ketoconazole, itraconazole)
• some medicines used to treat irregular heart beats (e.g. amiodarone and quinidine)
• pemetrexed, a medicine used in the treatment of certain lung cancers.

These medicines may be affected by Mobic or may affect how well it works. You may need different amounts of your medicines, or you may need different medicines.

Your doctor and pharmacist have more information on medicines to be careful with or avoid while taking this medicine.

How to take Mobic

Follow all directions given to you by your doctor or pharmacist carefully.

They may differ from the information contained in this leaflet.

How much to take

For the treatment of osteoarthritis
The usual dose of Mobic is 7.5 mg, taken as a single dose each day.

Depending on the severity of your condition and your response to treatment, your doctor may increase this dose to 15 mg taken as a single dose each day.

For the treatment of rheumatoid arthritis
The usual dose of Mobic is 15 mg taken as a single dose each day.

Depending on your response, your doctor may reduce this dose to 7.5 mg taken as a single dose each day.

The maximum recommended daily dose of Mobic is 15 mg.

For patients with kidney problems undergoing dialysis, the maximum recommended daily dose is 7.5 mg.

Ask your doctor for more information if you have been advised to take a different dose.

How to take it

Swallow the tablets or capsules whole with a full glass of water.

When to take it

Take your medicine at about the same time each day.

Taking it at the same time each day will have the best effect. It will also help you remember when to take it.

Take your medicine with or straight after food.

This may help reduce the possibility of stomach upset.

How long to take it

Continue taking your medicine for as long as your doctor tells you.

This medicine helps control your condition, but does not cure it. It is important to keep taking your medicine even if you feel well.

If you forget to take it

If it is almost time for your next dose (e.g. within 2-3 hours), skip the dose you missed and take the next dose when you are meant to.

Otherwise, take it as soon as you remember, then go back to taking it as you would normally.

Do not take a double dose to make up for the dose that you missed.

If you are not sure what to do, ask your doctor or pharmacist.

If you have trouble remembering to take your medicine, ask your pharmacist for some hints.

If you take too much (overdose)

Immediately telephone your doctor or Poisons Information Centre (telephone 13 11 26) for advice, or go to Emergency at your nearest hospital if you think that you or anyone else may have taken too much Mobic. Do this even if there are no signs of discomfort or poisoning.

You may need urgent medical attention.

Symptoms of an overdose may include:

• nausea and/or vomiting
• headache
• drowsiness and/or dizziness
• blurred vision
• fits or seizures
• low blood pressure
• difficulty in breathing
• impaired consciousness
• kidney failure.

While you are using Mobic

Things you must do

If you are about to be started on any new medicine, remind your doctor and pharmacist that you are taking Mobic.

Tell any other doctors, dentists, and pharmacists who treat you that you are taking this medicine.

If you are going to have surgery, tell the surgeon or anaesthetist that you are taking Mobic.

Mobic can slow down blood clotting.

If you become pregnant while taking this medicine, tell your doctor immediately.

If you get an infection while using Mobic, tell your doctor.

Mobic may hide some of the signs of an infection (e.g. pain, fever, redness and swelling). You may think, mistakenly, that you are better or that the infection is not serious.

Things you must not do

Do not take Mobic to treat any other complaints unless your doctor tells you to.

Do not give your medicine to anyone else, even if they have the same condition as you.

Do not stop taking your medicine or lower the dosage without checking with your doctor.

Things to be careful of

Be careful driving or operating machinery until you know how Mobic affects you.

This medicine may cause dizziness, drowsiness or blurred vision in some people. If you have any of these symptoms, do not drive, operate machinery or do anything else that could be dangerous.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking Mobic.

This medicine helps most people but it may have unwanted side effects in a few people. All medicines have side effects. Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects.

Do not be alarmed by the following lists of side effects. You may not experience any of them.

Not all of these side effects have been reported with Mobic but have been seen with similar medicines.

Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor or pharmacist if you notice any of the following and they worry you:

• stomach upset including: nausea, vomiting, heartburn, indigestion, belching, cramps or pain
• headache
• flu-like symptoms, runny or blocked nose, cough, sore mouth or throat, discomfort when swallowing
• constipation, diarrhoea or wind
• dizziness or light-headedness
• skin rashes, which may be caused by exposure to sunlight, can blister and may take on the appearance of a severe burn, or itching
• increase in blood pressure
• tinnitus (ringing in the ear).

The above list includes the more common side effects of your medicine. These side effects are usually mild.

Tell your doctor immediately if you notice any of the following:

• blurred vision
• any change in the amount or colour of your urine (red or brown) or any pain or difficulty experienced when urinating
• collapse or fainting, shortness of breath or tiredness, fast or irregular heartbeat, chest pain, swollen or sore leg veins
• severe dizziness
• severe pain or tenderness in the stomach
• flaking of the skin
• yellowing of the skin and eyes (known as jaundice)
• swelling of your ankles, legs or other parts of your body
• signs of anaemia (such as: tiredness, being short of breath and looking pale)
• irritation of your mucous membranes (e.g. lips, mouth, eyes or genitals).

These are rare but serious side effects. You may need urgent medical attention.

If any of the following happen, tell your doctor immediately or go to Emergency at your nearest hospital:

• vomiting of blood or material that looks like coffee grounds
• bleeding from your back passage (rectum), black sticky motions (stools) or bloody diarrhoea
• swelling of the face, lips or tongue which may make swallowing or breathing difficult
• asthma, wheezing or shortness of breath
• sudden or severe itching, skin rash or hives
• weakness in one part or side of your body, slurred speech, blurred vision or visual disturbances.

These are rare but very serious side effects. You may need urgent medical attention or hospitalisation.

Tell your doctor or pharmacist if you notice anything else that is making you feel unwell.

Other side effects not listed above may occur in some people.

After using Mobic

Storage

Keep your tablets or capsules in their pack until it is time to take them.

If you take them out of the pack they may not keep well.

Keep your tablets or capsules in a cool dry place where the temperature stays below 25°C.

Do not store Mobic or any other medicine in the bathroom or near a sink. Do not leave it on a window sill or in the car.

Heat and dampness can destroy some medicines.

Keep it where children cannot reach it.

A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Disposal

If your doctor tells you to stop taking this medicine or the expiry date has passed, ask your pharmacist what to do with any medicine that is left over.

Product description

What it looks like

Mobic is the brand name of your medicine. It is available as tablets or capsules in two strengths.

• Mobic 7.5 mg tablets – pastel-yellow, round tablets, marked 59D on one side with break bar, and company logo on the other.
  Available in blister packs of 10*, 20*, 30, 60* and 100* tablets.
• Mobic 15 mg tablets – pastel-yellow, round tablets, marked 77C on one side with break bar, and company logo on the other.
  Available in blister packs of 10*, 20*, 30, 60* and 100* tablets.
• Mobic 7.5 mg capsules – pale green capsules.
  Available in blister packs of 10*, 20*, 30 and 100* capsules.
• Mobic 15 mg capsules – pale yellow/pale green capsules.
  Available in blister packs of 10*, 20*, 30 and 100* capsules.

*Not distributed in Australia.

Ingredients

Active ingredient:

• Mobic 7.5 mg tablet or capsule – 7.5 mg of meloxicam.
• Mobic 15 mg tablet or capsule – 15 mg of meloxicam.

Inactive ingredients:
Mobic tablets also contain:

• sodium citrate dihydrate
• lactose monohydrate
• microcrystalline cellulose
• povidone
• crospovidone
• colloidal anhydrous silica
• magnesium stearate.

Mobic capsules also contain:

• sodium citrate dihydrate
• lactose monohydrate
• maize starch
• magnesium stearate
• gelatin
• indigo carmine CI73015
• iron oxide yellow CI77492
• titanium dioxide
• purified water.

Mobic does not contain gluten or sucrose.

Supplier

Mobic is supplied in Australia by:

BOEHRINGER INGELHEIM PTY LIMITED
ABN 52 000 452 308
78 Waterloo Road
North Ryde NSW 2113

This leaflet was revised in May 2017

® Mobic is a registered trademark of Boehringer Ingelheim.

© Boehringer Ingelheim Pty Limited 2017.

Australian Registration Number(s)

Mobic 7.5 mg tablets: AUST R 77694.
Mobic 15 mg tablets: AUST R 77695.
Mobic 7.5 mg capsules: AUST R 77698.
Mobic 15 mg capsules: AUST R 77699.

Mobic | Side Effects | Dosage | Precautions

By Medicover Hospitals / 11 Mar 2021
Home | Medicine | Mobic

What is Mobic?

1. Mobic Uses
2. Mobic Side effects
3. Precautions
4. Overdose
5. Storage
6. Mobic vs Celebrex
7. Frequently Asked Questions
8. Citations

Mobic Uses:

This medication is used to treat arthritis. It alleviates joint pain, swelling, and stiffness. It is a nonsteroidal anti-inflammatory medication (NSAID). Ask your doctor about non-drug treatments and/or using other medications to treat your pain if you have a chronic condition such as arthritis.

How to use :

• Before you begin taking this, and each time you get a refill, read the Medication Guide provided by your pharmacist. Also, inform your dosage schedule to the doctor.
• Take this medication orally, usually once daily, as directed by your doctor. Unless your doctor instructs you otherwise, drink a full glass of water (8 ounces/240 milliliters) with it. After taking this medication, do not lie down for at least 10 minutes.
• If you are taking this medication that is in liquid form, shake the bottle before each dose. Use a special measuring device to carefully measure the dose. You should not use a regular spoon because you may not get the correct dose.
• If you’re using a disintegrating tablet. Peel back the foil with dry hands to carefully remove the tablet. Do not force the tablet through the foil as this may cause it to break. Place the tablet on your tongue as soon as possible and allow it to dissolve. The tablet can be swallowed with or without liquid after it has melted.
• If you experience stomach upset while taking this medication, take it with food, milk, or an antacid. The dosage is determined by your medical condition as well as your response to treatment. The lowest effective dosage should always be used, and only for the time period prescribed. Do not take more than the recommended dose of this medication because higher doses increase the risk of stomach ulcers/bleeding.
• Mobic can be found in a variety of forms (such as a tablet, capsule, liquid, disintegrating tablet). Do not switch between forms without first consulting your doctor.
• It could take up to two weeks before you feel the full effects of this medication. To get the most out of this medication, take it on a regular basis.

Mobic Side Effects:

• Bleeding gums
• Bloating
• Blood in the urine
• Blurred vision
• Abdominal or stomach pain
• Canker sores
• Chest tightness or heaviness
• Chills
• Nausea
• Cloudy urine
• Cough
• Cramping
• Dark urine
• Difficult breathing
• Dilated neck veins
• Dizziness

Precautions:

• Tell your doctor or pharmacist about your medical history, especially if you have: asthma, liver disease, stomach problems (such as bleeding, ulcers, or recurring heartburn), heart disease, high blood pressure, stroke, a blood disorder, or nose growths.
• NSAID medications can occasionally cause kidney problems. If you are dehydrated, have heart failure or kidney disease, are an older adult, or take certain medications, you are more likely to have problems. Drink plenty of fluids as directed by your doctor to avoid dehydration, and notify your doctor immediately if the amount of urine changes.
• This medication can cause stomach bleeding. The use of alcohol and tobacco on a regular basis, particularly when combined with this medication, may increase your risk of stomach bleeding. Limit your consumption of alcohol.
• Disintegrating tablets may contain aspartame. If you have phenylketonuria (PKU) or another condition that requires you to limit or avoid aspartame (or phenylalanine) in your diet, consult with your doctor or pharmacist about how to use this medication safely.
• While taking this medication, older adults may be more likely to experience stomach/intestinal bleeding, kidney problems, a heart attack, or a stroke.
• Before taking this medication, women of childbearing age should discuss the benefits and risks with their doctor. Inform your doctor if you are pregnant. This medication is the potential in giving harm to an unborn baby and causing complications during normal labor and delivery. It is not advised to be used during pregnancy from 20 weeks until delivery. If your doctor determines that you must take this medication between 20 and 30 weeks of pregnancy, you should take the lowest effective dose for the shortest amount of time. This medication should not be used after 30 weeks of pregnancy.
• It is unknown whether this medication is excreted in breast milk or not. Similar drugs, on the other hand, pass into breast milk and are unlikely to harm a nursing infant. Before breastfeeding, talk to your doctor.

Interactions:

• Aliskiren, ACE inhibitors (such as captopril and lisinopril), angiotensin II receptor blockers (such as losartan and valsartan), cidofovir, lithium, methotrexate (high-dose treatment), and water pills are some products that may interact with this medication (diuretics such as furosemide).
• When combined with other drugs which might cause bleeding, this medication may increase the risk of bleeding. Antiplatelet drugs such as clopidogrel and blood thinners such as dabigatran/enoxaparin/warfarin are examples.
• If you are taking mobic in liquid form, tell your doctor if you are also taking sodium polystyrene sulfonate.

Overdose:

Missed Dose:

Storage:

The medicine should not come in direct contact with heat, air, light and may damage your medicines. Exposure to medicine might cause some harmful effects or serious side effects. The medicine must be kept in a safe place and out of children’s reach.

Mobic vs Celebrex:

Frequently Asked Questions:

Mobic is a nonsteroidal anti-inflammatory medication (NSAID). It works by lowering hormones in the body that cause inflammation and pain. Mobic is an anti-inflammatory medication used to treat the pain and inflammation caused by rheumatoid arthritis and osteoarthritis in adults.

The main distinctions between mobic and ibuprofen are as follows: mobic is a more potent medication than ibuprofen. Mobic is only available by prescription, whereas ibuprofen is available both over the counter and by prescription.

Mobic’s side effects do not include drowsiness (in fact, it can cause insomnia), but they do include dizziness. However, headache is a common and minor side effect of this medicine.

One of its side effects includes weight gain. So it may or may not lead to a gain in weight.

For people with kidney disease: If you take mobic for a long time, it may decrease your kidney function, making your kidney disease worse.

Mobic (meloxicam) and Ultram (tramadol) are pain relievers. Mobic is used to treat arthritis pain and inflammation. Ultram is a pain reliever that is used to treat moderate to severe pain in adults.

Take each dose with a snack or immediately after eating a meal, and drink plenty of water while taking a mobic. If your doctor has prescribed melt-in-the-mouth (orodispersible) tablets, moisten your mouth first, sipping water if necessary.

Mobic is a medication used to treat arthritis. It alleviates joint pain, swelling, and stiffness.

The use of mobic helps patients control pain from injuries of the nerve.

Adults –7.5 milligrams (mg) once a day at first. However, the usual dose is no more than 15 mg once a day. The maximum recommended daily oral dosage in an adult is 15 mg.

LABELLING

%PDF-1.4
%
1 0 obj
>
endobj
7 0 obj

/ModDate (D:20170727151525+01’00’)
/Producer
/Subject (General-EMEA/378973/2008)
/Title (LABELLING)
>>
endobj
2 0 obj
>
endobj
3 0 obj
>
stream

endstream
endobj
4 0 obj
>
endobj
5 0 obj
>
endobj
6 0 obj
>
endobj
8 0 obj
6442
endobj
9 0 obj
>
stream
xwTTϽwz0tzRWQf

Ask the Doctors – How does meloxicam ease joint pain?

2. Wellness
3. Healthy Living
4. Ask the Doctors – How does meloxicam ease joint pain?

By Ask the Doctors • August 29, 2018

Dear Doctor: I’ve suffered joint pain for years. Being prescribed 15 milligrams of Meloxicam has been wonderful. What are your thoughts on Meloxicam use?

Dr. Robert Ashley

Meloxicam (Mobic) is a non-steroidal anti-inflammatory drug (NSAID) that, like all such drugs, inhibits the formation of the enzyme cyclooxygenase (COX). This inhibition leads to a decrease in the production of molecules that boost inflammation and help the blood clot.

There are two forms of the COX enzyme, aptly named COX-1 and COX-2. COX-1 is involved in protecting the lining of the stomach, promoting the blood’s clotting ability and aiding kidney function. COX-2 is involved in the inflammatory response in the body. Many of the side effects seen with older NSAIDs such as ibuprofen, naproxen and diclofenac are related to the inhibition of COX-1. The side effects include gastritis or gastric ulcers, blood thinning and kidney damage. Inhibiting COX-2 leads to a decrease in inflammation and a decrease in pain.

Meloxicam at low doses (7.5 milligrams) inhibits COX-2 and not COX-1.  That means it can reduce pain and inflammation, without irritation of the stomach lining or an increased risk of stomach ulcers. Research has found that serious upper gastrointestinal events at the 7.5 mg dose occur in fewer than 1 in 3,000 people. But note that follow-up studies didn’t last more than 60 days, so it’s unclear if these rates would hold up over the long term.

Further, at low doses, meloxicam may not show the kidney problems that other NSAIDs cause. The rates of heart attacks appear comparable to those of other NSAIDs, with a slight increase in risk at all doses.

However, when meloxicam dosage is increased to 15 milligrams, the medication does inhibit COX-1, leading to a significant increase in the rates of serious upper gastrointestinal events. One study found that, while the number of events was less than with the NSAID naproxen, the number of events at 15 mg was six times higher than the lower dose of meloxicam (1 in 500 people). Another study showed a greater proportion of people with a slight decrease in kidney function when 22.5 mg of meloxicam was taken for 12 weeks. This was not seen at the 15 mg dosage. Lastly, for people on two types of blood pressure drugs – ACE-inhibitors and angiotensin receptor blockers, meloxicam (like other NSAIDs) may make those medications less effective. One note for people who take either ACE inhibitors or angiotensin receptor blockers for high blood pressure: Meloxicam may make these medication less effective

In summary, meloxicam works well for pain and swelling. The higher doses do decrease pain more than the 7.5mg dosage, and the medication is comparable to the NSAID diclofenac for both pain relief and decreasing inflammation. I have frequently recommended the medication for joint inflammation, bone bruises, pain from fractures and tendonitis, and it’s worked well for the vast majority of my patients. For older adults, I lean toward the 7.5 mg dose, but I have recommended 15 mg in more severe cases. Some of the latter group have complained of gastrointestinal discomfort, but this stopped when they discontinued the medication. I rarely give this medication for greater than one month, but have had some patients who have been on this medication for years for severe arthritis.

I don’t know how frequently you are using meloxicam, but if you’re using it on an as-needed basis, it should be safe. If you’re using this medication daily, you should consider its potential for side effects.

Robert Ashley, MD, is an internist and assistant professor of medicine at the University of California, Los Angeles.

Ask the Doctors is a syndicated column first published by UExpress syndicate.

Tags: Aging, arthritis, Ask the Doctors, Ask the Doctors, Children’s Health, diclofenac, Dr. Robert Ashley, Healthy Living, joint pain, meloxicam, naproxen, NSAIDs, Wellness

Related Posts

The device requires no surgery and may theoretically lower the risk of sudden death from epilepsy

There are a number of benefits when it comes to intermittent fasting

What’s the difference between antigen and PCR tests, and what’s the best way to use them?

ACT Meloxicam – Uses, Side Effects, Interactions

Meloxicam belongs to the family of medications known as COX-2 inhibiting nonsteroidal anti-inflammatory drugs (NSAIDs). It is used to treat rheumatoid arthritis and painful osteoarthritis in adults. It helps with these conditions by relieving pain and reducing swelling and inflammation.

NSAIDs work by blocking a response to injury in the body that leads to inflammation and pain.

This medication may be available under multiple brand names and/or in several different forms. Any specific brand name of this medication may not be available in all of the forms or approved for all of the conditions discussed here. As well, some forms of this medication may not be used for all of the conditions discussed here.

Your doctor may have suggested this medication for conditions other than those listed in these drug information articles. If you have not discussed this with your doctor or are not sure why you are taking this medication, speak to your doctor. Do not stop taking this medication without consulting your doctor.

Do not give this medication to anyone else, even if they have the same symptoms as you do. It can be harmful for people to take this medication if their doctor has not prescribed it.

7.5 mg
Each light yellow, round, biconvex, bevelled-edged tablet with ” > ” on one side and “ML” over “7.5” on the other contains 7.5 mg of meloxicam. Nonmedicinal ingredients: colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium citrate.

15 mg
Each light yellow, convex, bevelled-edged, round tablet with ” > ” on one side and “ML” over “15” on the other contains 15 mg meloxicam. Nonmedicinal ingredients: colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium citrate.

Rheumatoid arthritis: The usual starting dose of meloxicam to treat the symptoms of rheumatoid arthritis is 15 mg once daily. For some people who may respond well to the medication, their doctor can reduce the dose to 7.5 mg once daily, according to need.

Osteoarthritis: The recommended dose to relieve osteoarthritis pain is 7.5 mg once daily. The doctor may increase this to 15 mg taken once daily if necessary.

For both conditions, the maximum dose of meloxicam is 15 mg taken once daily.

This medication may be taken with or without food.

The use of this medication should be limited to the lowest effective dose for the shortest period of time needed.

Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.

It is important to take this medication exactly as prescribed by your doctor. If you miss a dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.

Store this medication at room temperature, protect it from light and moisture, and keep it out of the reach of children.

Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.

What side effects are possible with this medication?

Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.

The side effects listed below are not experienced by everyone who takes this medication. If you are concerned about side effects, discuss the risks and benefits of this medication with your doctor.

The following side effects have been reported by at least 1% of people taking this medication. Many of these side effects can be managed, and some may go away on their own over time.

Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.

• constipation
• diarrhea
• dizziness or lightheadedness
• drowsiness
• flushing
• gas/flatulence
• headache
• indigestion
• mouth ulcers
• nausea
• sensitivity to sunlight
• sleepiness
• sore mouth
• uncomfortable feeling in the stomach
• weight changes

Although most of these side effects listed below don’t happen very often, they could lead to serious problems if you do not seek medical attention.

Check with your doctor as soon as possible if any of the following side effects occur:

• confusion
• eye infection (e.g., swollen runny eyes, itching eyes, crusty eyelids)
• hearing problems
• high blood pressure
• pain while urinating or difficulty urinating
• pounding heart beat
• ringing in the ears
• signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
• signs of clotting problems (e.g., unusual nosebleeds, bruising, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding)
• signs of depression (e.g., poor concentration, changes in weight, changes in sleep, decreased interest in activities, thoughts of suicide)
• signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness)
• signs of kidney problems (e.g., increased urination at night, decreased urine production, blood in the urine, painful or difficult urination)
• signs of liver damage (e.g., yellow skin or eyes, abdominal pain, dark urine, clay-coloured stools, loss of appetite, nausea and vomiting, or itching)
• skin rash or itching
• small, red spots on skin
• swelling of the lower legs, ankles, or feet
• unexplained weight gain
• vision changes including blurred vision
• vomiting or persistent nausea, indigestion, stomach pain, or diarrhea

Stop taking the medication and seek immediate medical attention if any of the following occur:

• changes in the amount or colour of urine (such as red or brown urine)
• fainting
• rapid swelling of face, tongue, lips
• seizures
• severe stomach pain
• shortness of breath
• signs of bleeding in the stomach (e.g., bloody, black, or  tarry stools, spitting up of blood, vomiting blood or material that looks like coffee grounds)
• signs of breathing problems (e.g., shortness of breath, troubled breathing, wheezing, or tightness in chest, fast or irregular breathing)
• signs of meningitis not caused by infection (e.g., headache (severe), throbbing, or with stiff neck or back)
• signs of a severe allergic reaction (e.g., hives, difficulty breathing, swelling of the face, mouth, throat, or tongue)
• signs of a severe skin reaction (e.g., blistering, peeling, a rash covering a large area of the body, a rash that spreads quickly, or a rash combined with fever or discomfort)

Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking this medication.

Are there any other precautions or warnings for this medication?

Before you begin using a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use this medication.

HEALTH CANADA ADVISORY

June 8, 2021

Health Canada has issued new information concerning the use of non-steroidal anti-inflammatory drugs (NSAIDs). To read the full Health Canada Advisory, visit Health Canada’s web site at www.hc-sc.gc.ca.

A previous advisory on non-steroidal anti-inflammatory drugs (NSAIDs) was issued on October 30, 2020.

Alcohol: People taking this medication should not drink alcohol, as this can increase the risk of stomach problems with the medication.

Allergic reactions: If you have had a reaction to acetylsalicylic acid (ASA) or other NSAIDs (e.g., ibuprofen, ketoprofen, diclofenac) that included a runny nose, itchy skin rash, nasal polyps, or shortness of breath and wheezing, you should not take this medication. If you experience symptoms of a severe allergic reaction (e.g., hives; difficulty breathing, wheezing; swelling of the face, tongue, or throat), get immediate medical attention.

Aseptic meningitis: This medication can rarely cause symptoms of aseptic meningitis (inflammation or swelling of the membranes around the brain and spinal cord that is not caused by bacteria). If you have an autoimmune condition (e.g., systemic lupus erythematosus, mixed connective tissue disease), you are more at risk for developing this. If you experience symptoms such as stiff neck, severe headache, nausea, vomiting, fever, or changes in consciousness, stop taking this medication and get immediate medical attention.

Bladder symptoms: This medication can cause bladder symptoms such as frequent or painful urination and blood in urine. If you develop these symptoms, stop taking this medication and contact your doctor immediately.

Blood counts: This medication can decrease the number of neutrophils (a type of white blood cell that helps fight infection), red blood cells (which carry oxygen), and platelets (which help your blood to clot). Your doctor will do blood tests to monitor this. Contact your doctor immediately if you notice an increased occurrence of signs of infection (e.g., fever, chills, or sore throat), feel unusually tired, lack energy, or experience unusual bleeding or bruising.

Blood pressure: Like other NSAIDs, meloxicam can cause increased blood pressure, which may contribute to other heart conditions. If you have high blood pressure, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.

Drowsiness/reduced alertness: Meloxicam may reduce mental or physical abilities required for performance of hazardous tasks such as operating machinery or driving a motor vehicle. Avoid these and other hazardous tasks until you are sure that this medication does not affect your ability to do these safely.

Fertility: Fertility may be decreased in people taking this medication. This medication is not recommended for women who are trying to get pregnant.

Galactose intolerance/glucose malabsorption: Meloxicam medications are prepared with lactose. If you have lactose or galactose intolerance you should not take these medications.

Heart attack and stroke: The use of COX-2 NSAIDs, including meloxicam, is associated with an increased risk of heart attack and stroke. This risk is increased with higher total daily doses and taking the medication over long periods of time. If you have a history of heart disease, including heart attack and stroke, discuss with your doctor the benefits and risks of taking this medication. Ask your doctor about all available treatment options that may be right for you.

Heart conditions: This medication can cause fluid retention which will make symptoms of certain heart conditions worse. If you have heart failure, high blood pressure, or other medical conditions that increase your risk of fluid retention (e.g., kidney problems), discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.

Infection: This medication may mask signs of infection such as fever or muscle aches. If you notice other symptoms of infection (e.g., painful or frequent urination, sore throat, cough) contact your doctor.

Informing health professionals: Be sure to tell any health professionals (including your doctor, nurse, pharmacist, and dentist) involved in your care that you are taking this medication, particularly if you are scheduled for heart surgery.

Kidney function: This medication can affect kidney function. You have a higher risk of developing kidney problems if you are a senior, take diuretics (water pills; e.g., hydrochlorothiazide, furosemide), or already have kidney disease or heart failure. Your doctor may monitor your kidney function with blood tests when you are taking this medication. Meloxicam is not recommended for people with severely reduced kidney function if they are not receiving dialysis.

Liver function: This medication may affect your liver function or cause liver problems. If you experience symptoms of liver problems (e.g., nausea, vomiting, feeling tired, yellowing of the skin or eyes) contact your doctor immediately. If you have liver problems, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. People with severely reduced liver function or have active liver disease should not take this medication.

Potassium levels: Meloxicam may cause high blood potassium levels. You are more at risk of high blood potassium if you are a senior, have diabetes or kidney failure, or are taking beta-blockers (e.g., metoprolol, atenolol), angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril, enalapril), or some diuretics (e.g., triamterene, amiloride). Because extremely high blood potassium levels can contribute to other conditions, such as heart problems, your doctor will monitor your potassium level with blood tests while you are taking this medication.

Ulcers and bleeding in the stomach and intestines: This medication may cause stomach ulcers and bleeding from the stomach. These complications can occur at any time and are sometimes severe.

If you have had a stomach or intestinal ulcer, diverticulosis, Crohn’s disease or ulcerative colitis, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.

If you experience symptoms of an ulcer or other stomach problems (e.g., stomach or abdominal pain, black stools, blood or coffee grind-like vomit, weakness), contact your doctor immediately or get immediate medical attention.

Pregnancy: This medication should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking this medication, contact your doctor immediately. It must not be used during the last 3 months of pregnancy as it may cause heart and kidney problems for the developing baby and cause prolonged labour with excessive bleeding during delivery.

Breast-feeding: Many anti-inflammatory medications are known to pass into breast milk. If you are a breast-feeding mother and are taking meloxicam, it may affect your baby. Breast-feeding is not recommended while you are taking meloxicam.

Children: The safety and effectiveness of using this medication have not been established for children.

Seniors: Seniors may have a higher risk of side effects and should be closely monitored by their doctors while taking this medication.

What other drugs could interact with this medication?

There may be an interaction between meloxicam and any of the following:

• acetylsalicylic acid (ASA)
• alcohol
• aliskiren
• alteplase
• aminoglycoside antibiotics (e.g., amikacin, gentamicin, tobramycin)
• angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril, enalapril, captopril, quinapril)
• angiotensin receptor blockers (ARBs; e.g., candesartan, irbesartan, losartan)
• apixaban
• “azole” antifungals (e.g., itraconazole, ketoconazole, voriconazole)
• beta-adrenergic blockers (e.g., atenolol, propranolol, sotalol)
• bimatoprost
• bisphosphonates (e.g., alendronate, etidronate)
• bosentan
• carbamazepine
• celecoxib
• cholestyramine
• clopidogrel
• colestipol
• cyclosporine
• dabigatran
• dabrafenib
• dasatinib
• deferasirox
• desmopressin
• digoxin
• dipyridamole
• diuretics (water pills; e.g., furosemide, hydrochlorothiazide, triamterene)
• edoxaban
• eplerenone
• glucosamine
• haloperidol
• heparin
• herbal products that affect blood clotting (e.g., cat’s claw, chamomile, evening primrose, feverfew, fenugreek, garlic, ginger, ginseng, turmeric)
• hydralazine
• ibrutinib
• latanoprost
• lithium
• low-molecular-weight heparins (e.g., dalteparin, enoxaparin, tinzaparin)
• mesalamine
• methotrexate
• mifepristone
• milk thistle
• multivitamins (with vitamins A, E) with or without minerals
• non-steroidal anti-inflammatory medications (NSAIDs; e.g., diclofenac, ibuprofen, naproxen)
• obinutuzumab
• omega-3 fatty acids
• oral corticosteroids (e.g., dexamethasone, hydrocortisone, prednisone)
• pemetrexed
• pentoxifylline
• prasugrel
• quinine
• quinolone antibiotics (e.g., ciprofloxacin, norfloxacin, ofloxacin)
• rifampin
• rivaroxaban
• selective serotonin reuptake inhibitors (SSRIs; e.g., citalopram, fluoxetine, paroxetine, sertraline)
• serotonin/norepinephrine reuptake inhibitors (SNRIs; e.g., desvenlafaxine, duloxetine, venlafaxine)
• sodium phosphates
• sodium polystyrene sulfonate
• sulfasalazine
• tacrolimus
• tenofovir
• ticagrelor
• ticlopidine
• tipranavir
• tricyclic antidepressants (e.g., amitriptyline, clomipramine, desipramine, trimipramine)
• urokinase
• vancomycin
• vitamin E
• warfarin

If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:

• stop taking one of the medications,
• change one of the medications to another,
• change how you are taking one or both of the medications, or
• leave everything as is.

An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.

Medications other than those listed above may interact with this medication. Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.

All material copyright MediResource Inc. 1996 – 2021. Terms and conditions of use. The contents herein are for informational purposes only. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Source: www.medbroadcast.com/drug/getdrug/ACT-Meloxicam

Memorial Sloan Kettering Cancer Center

This document, provided by Lexicomp ^® , contains all the information you need to know about the drug, including the indications, route of administration, side effects and when you should contact your healthcare provider.

Trade names: USA

Anjeso; Mobic; Qmiiz ODT; Vivlodex

Trade names: Canada

ACT Meloxicam [DSC]; APO-Meloxicam; Auro-Meloxicam; DOM-Meloxicam; Mobicox [DSC]; MYLAN-Meloxicam [DSC]; PMS-Meloxicam; TEVA-Meloxicam

Warning

• This drug may increase the risk of heart and blood vessel problems, such as heart attack and stroke.These effects can be deadly. This risk may be increased if you have heart disease or have risk factors for such diseases. However, the risk may be increased even for people who do not have or are not at risk of developing heart disease. The risk may arise during the first weeks of using this drug and may increase with higher doses or with long-term use. This drug should not be used immediately before or after coronary artery bypass surgery.
• This drug may increase the chance of severe and sometimes fatal stomach or intestinal problems such as ulcers or bleeding. The risk is increased in the elderly and in people who have previously had ulcers or bleeding in the stomach or intestines. Such violations can occur suddenly.

What is this drug used for?

• Used to treat some types of arthritis.
• Used to relieve pain.
• This medicinal product can be used for other indications. Consult your doctor.

What should I tell my doctor BEFORE taking this drug?

All forms of issue:

• If you are allergic to this drug, any of its ingredients, other drugs, foods or substances. Tell your doctor about your allergy and how it manifested itself.
• If you are allergic to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen.
• If you have any of the following health problems: gastrointestinal bleeding or kidney problems.
• If you have any of the following health conditions: Heart failure (weak heart) or have recently had a myocardial infarction.
• If you are taking NSAIDs, a salicylate such as aspirin, or pemetrexed.
• If you are unable to get pregnant or are checking if you are able to get pregnant.
• If you are pregnant, plan to become pregnant, or become pregnant while taking this drug.If you take this drug after 20 weeks of pregnancy, it can cause fetal harm. If you are between 20 and 30 weeks pregnant, take this drug only as directed by your doctor. Do not use this drug after 30 weeks of pregnancy.

Suspension:

• If you are taking sodium polystyrene sulfonate.

Lozenge:

• If you have phenylketonuria (PKU). This medicine contains phenylalanine.

This list of drugs and diseases that may be adversely associated with this drug is not exhaustive.

Tell your doctor and pharmacist about all medicines you take (both prescription and over-the-counter, natural products and vitamins) and your health problems. You need to make sure that this drug is safe for your medical conditions and in combination with other drugs you are already taking.Do not start or stop taking any medication or change the dosage without your doctor’s approval.

What do I need to know or do while taking this drug?

• Tell all healthcare providers that you are taking this drug. These are doctors, nurses, pharmacists and dentists.
• Do not take the drug in higher doses than the doctor prescribed. Taking more than the prescribed amount of the drug increases the risk of serious side effects.
• Do not take this drug for longer than your doctor prescribed.
• With long-term use of the drug, a blood test must be performed. Talk to a medical professional.
• High blood pressure has been reported with this type of drug. Monitor your blood pressure as directed by your doctor.
• Consult a physician before drinking alcohol.
• If you smoke, consult your doctor.
• If you have asthma, consult your doctor. You may be more sensitive to the drug.
• There is an increased likelihood of bleeding. Be careful and avoid injury. Use a soft toothbrush and electric shaver.
• The risk of developing heart failure is increased with the use of drugs of this kind. People with heart failure have an increased risk of myocardial infarction, hospitalization for heart failure, and death.Consult your doctor.
• People who have had myocardial infarction and are taking drugs of this kind have an increased risk of recurrence of myocardial infarction and death due to heart problems. People who took drugs of this kind after their first heart attack were also more likely to die one year after myocardial infarction compared with those who did not take these drugs. Consult your doctor.
• If you are taking aspirin to prevent myocardial infarction, consult your doctor.
• Liver dysfunctions have been reported while taking drugs of this kind. Sometimes these cases were fatal. Call your doctor right away if you have signs of liver dysfunction, such as dark urine, tired feeling, lack of appetite, nausea or abdominal pain, light colored stools, vomiting, yellow skin or eyes.
• Severe and sometimes fatal reactions have occurred with other drugs of this nature. In most cases, this reaction was accompanied by symptoms such as fever, rash, inflammation of the lymph nodes, and dysfunction of various organs such as the liver, kidneys, blood, heart, muscles, joints and lungs. If you have any questions, please consult your doctor.
• If you are 65 years of age or older, use this drug with caution.You may have more side effects.
• Non-steroidal anti-inflammatory drugs (NSAIDs), such as this drug, can interfere with egg release (ovulation). This can negatively affect your ability to get pregnant. As a rule, the ovulation process is restored after you stop taking this drug. Consult your doctor.
• This drug has caused reproductive disorders in male animals. Reproductive disorders can negatively affect a man’s ability to conceive.There are no data on the possibility of subsequent normalization of reproductive function in the event of this effect.
• Tell your doctor if you are breastfeeding. It is necessary to consult if the drug poses any risk to the child.

What side effects should I report to my doctor immediately?

WARNING. In rare cases, some people with this drug can cause serious and sometimes deadly side effects.Call your healthcare professional or get medical attention right away if you have any of the following signs or symptoms, which may be associated with serious side effects:

• Signs of an allergic reaction such as rash, hives, itching, reddened and swollen skin with blistering or scaling, possibly associated with fever, wheezing or wheezing, tightness in the chest or throat, difficulty breathing, swallowing or speaking, unusual hoarseness, swelling in the mouth, face, lips, tongue, or throat.
• Signs of bleeding such as vomiting or coughing up blood; vomiting like coffee grounds; blood in the urine; black, red, or tarry stools; bleeding from the gums; non-cyclic vaginal bleeding; bruising that occurs or increases for no reason; bleeding that you cannot stop.
• Signs of kidney problems, including lack of urination, change in urine volume, blood in the urine, or rapid weight gain.
• Signs of elevated potassium levels such as a feeling of disturbed heartbeat, confusion, feeling weak or dizzy, feeling light-headed, feeling numb or tingling, or shortness of breath.
• Signs of high blood pressure, such as very severe headache, or dizziness, or loss of consciousness, or blurred vision.
• Shortness of breath, sudden weight gain, or swelling of the arms or legs.
• Pain or pressure in the chest.
• Weakness on one side of the body, difficulty speaking or thinking, trouble maintaining balance, drooping one side of the face, or blurred vision.
• Feeling extremely tired or weak.
• Flu-like symptoms.
• Swelling of the gland.
• Possible severe skin reaction (Stevens-Johnson syndrome / toxic epidermal necrolysis). This can lead to serious and permanent health problems and sometimes death. Get immediate medical attention if you experience symptoms such as redness, skin swelling with blistering or scaling (with or without a high fever), redness or irritation of the eyes, and ulceration in the mouth, throat, nose, or eyes.

What are some other side effects of this drug?

Any medicine can have side effects. However, many people have little or no side effects. Call your doctor or get medical help if these or any other side effects bother you or do not go away:

All oral preparations:

• Constipation, diarrhea, abdominal pain, nausea, vomiting, or decreased appetite.
• Dizziness or headache.
• Heartburn.
• Gas.
• Signs of a cold.

Injection:

This list of possible side effects is not exhaustive. If you have any questions about side effects, please contact your doctor. Talk to your doctor about side effects.

You can report side effects to the National Health Office.

You can report side effects to the FDA at 1-800-332-1088. You can also report side effects at https://www.fda.gov/medwatch.

What is the best way to take this drug?

Use this drug as directed by your healthcare practitioner. Read all the information provided to you. Follow all instructions strictly.

All oral preparations:

• Take with or without food.Take with food if the medicine causes nausea.

Suspension:

• Shake well before use.
• Care should be taken to measure liquid doses. Use the dispenser that comes with the medicine. If a dispenser is not included in the package, ask your pharmacist for a dosing product for this drug.

Lozenge:

• Do not remove this drug from the blister pack until you are ready to use it.Take this drug right after you open the blister pack. Do not store the removed drug for future use.
• Do not squeeze a tablet out of the foil when opening. The tablet should be removed from the foil with dry hands. Place the tablet on your tongue and let it dissolve. There is no need to drink water. Do not chew, break, or crush the tablet.

Injection:

• For intravenous injection.

What should I do if a dose of a drug is missed?

All oral preparations:

• Take the missed dose as soon as you can.
• If it is time for your next dose, do not take the missed dose and then return to your normal dose.
• Do not take 2 doses at the same time or an additional dose.

Injection:

• Call your doctor for further instructions.

How do I store and / or discard this drug?

All oral preparations:

• Store at room temperature in a dry place. Do not store in the bathroom.
• Protect from heat.

Capsules, tablets and suspensions:

• The lid must be tightly closed.

Capsules:

• Store in primary container.

Injection:

• If you need to store this drug at home, ask your doctor, nurse, or pharmacist for information about how it is stored.

All forms of issue:

• Store all medicines in a safe place. Keep all medicines out of the reach of children and pets.
• Dispose of unused or expired drugs. Do not empty into toilet or drain unless directed to do so. If you have any questions about the disposal of your medicinal products, consult your pharmacist.Your area may have drug recycling programs.

General information on medicinal products

• If your health does not improve or even worsens, see your doctor.
• You should not give your medicine to anyone and take other people’s medicines.
• Some medicines may have different patient information sheets. If you have questions about this drug, talk with your doctor, nurse, pharmacist, or other healthcare professional.
• A separate patient instruction sheet is attached to the product. Please read this information carefully. Reread it every time you replenish your supply. If you have questions about this drug, talk with your doctor, pharmacist, or other healthcare professional.
• If you think there has been an overdose of a drug, call a Poison Control Center immediately or seek medical attention. Be prepared to tell or show which drug you took, how much and when it happened.

Use of information by the consumer and limitation of liability

This information should not be used to make decisions about taking this or any other drug. Only the attending physician has the necessary knowledge and experience to make decisions about which drugs are appropriate for a particular patient. This information does not guarantee that the drug is safe, effective, or approved for the treatment of any disease or specific patient.Here are only brief general information about this drug. It does NOT contain all available information on the possible use of the drug with instructions for use, warnings, precautions, information about interactions, side effects and risks that may be associated with this drug. This information should not be construed as a guide to treatment and does not replace the information provided to you by your healthcare professional. Check with your doctor for complete information on the possible risks and benefits of taking this drug.Use of this information is governed by the Lexicomp End User License Agreement available at https://www.wolterskluwer.com/en/solutions/lexicomp/about/eula.

Copyright

© UpToDate, Inc. and its affiliates and / or licensors, 2021. All rights reserved.

Meloxicam instructions for use (tablets)

90,000 Side effects of meloxicam: general, rare and serious

Disclaimer

If you have any medical questions or concerns, please contact your doctor. Articles in the Health Guide are based on peer-reviewed research and information gleaned from medical societies and government agencies.However, they are not a substitute for professional medical advice, diagnosis, or treatment.

Meloxicam is a prescription nonsteroidal anti-inflammatory drug used to relieve joint pain associated with certain types of arthritis. The most common side effects of meloxicam are diarrhea, indigestion and flu symptoms (FDA, 2012). Headache, dizziness, skin rashes, and other gastrointestinal problems such as heartburn, nausea, and gas.side effects are also possible (DailyMed, 2019).

Vitals

• Black Box Warning: Meloxicam may increase the risk of heart attacks and strokes, especially in people with heart disease or other cardiovascular risk factors. This risk may be higher if you take meloxicam for a long time. Do not use meloxicam to treat pain immediately before or after heart surgery, such as after a coronary artery bypass graft (CABG) procedure.Meloxicam may also increase the risk of bleeding, ulcers, and holes (perforations) in the stomach or intestines.
• Meloxicam is a prescription non-steroidal anti-inflammatory drug (NSAID) used to treat pain and swelling associated with inflammatory conditions such as rheumatoid arthritis and osteoarthritis.
• Common side effects of meloxicam include diarrhea, headache, dizziness, and nausea.
• Meloxicam reduces platelet function, which may increase the risk of bleeding.
• One of the most serious potential side effects of meloxicam is an increased risk of gastrointestinal (GI) problems, including bleeding, ulcers, or perforations (holes) in the stomach or intestines.

All NSAIDs, even those available without a prescription (such as aspirin and ibuprofen), can cause serious side effects, which is why the US Food and Drug Administration (FDA) has issued a black box warning of serious side effects of meloxicam…. The black box warning is the FDA’s most stringent precautions for drugs with serious risk.

One of the most serious potential side effects of meloxicam is an increased risk of gastrointestinal (GI) problems, including bleeding, ulcers, or perforations (holes) in the stomach or intestines. These conditions can occur without warning and can be fatal.

Older adults and those with previous gastrointestinal problems taking meloxicam are at a higher risk of these side effects (FDA, 2012).Get immediate medical attention if you develop any signs of stomach ulcers such as bloody or dark stools (tarry stools), vomiting with or without blood, loss of appetite, difficulty breathing, or sudden stomach pain that does not go away (NIH, 2014).

how to make your penis grow

Advert

More than 500 generics at $ 5 per month

Go to Ro Pharmacy to get prescription drugs for just $ 5 per month each (no insurance).

What makes clindamycin for acne

Learn More

Although meloxicam is usually prescribed as a pill, other forms of this prescription drug are not taken by mouth. Meloxicam does not need to be taken orally to cause digestive problems. It does the same when given by injection, a form used in a hospital setting.

Meloxicam may also increase the risk of bleeding. Meloxicam interferes with normal platelet function, impaired platelet clumping ability, and slow clotting time (Rinder, 2002; Martini, 2014).This is of particular concern if you are taking other blood thinning medications or if you have a history of strokes or falls.

What is meloxicam and what is it used for?

Meloxicam is FDA approved for the treatment of joint pain associated with osteoarthritis (the most common form of arthritis, usually caused by wear and tear on the joints), rheumatoid arthritis or RA (a chronic inflammatory condition), and juvenile rheumatoid arthritis (RA affecting children as young as two years and older) (FDA, 2012).Although there is currently no cure for these conditions, pain can be managed with NSAIDs such as meloxicam.

Meloxicam may also be used off-label to treat pain associated with flare-ups of gout. Gout is a painful type of arthritis characterized by sudden pain, redness, and swelling that most commonly affects one joint of the big toe, but can occur anywhere in the body.

Meloxicam warnings: important things you need to know

7 minutes to read

This condition occurs due to the build-up of uric acid in the body and a number of behavioral factors can trigger flare-ups or seizures in susceptible individuals (Jin, 2012).Certain foods, such as shellfish and red meat, and medications, such as aspirin and certain diuretics (water pills), increase uric acid levels in the body (ACR, 2019). The best way to treat gout is to avoid triggers, however meloxicam can be used to help manage gout symptoms and relieve pain and swelling (Gaffo, 2019).

How to increase blood flow to the penis

Meloxicam Dosage and Trademarks

Meloxicam is available as a generic drug and sold under the trade names Mobic and Vivlodex.Generic and brand name meloxicam tablets are available in 5 mg, 7.5 mg, 10 mg, and 15 mg dosages. There are several forms of this medication. Meloxicam is available as an oral suspension (7.5 mg / 5 ml), a disintegrating tablet (doses of 7.5 mg and 15 mg), and an intravenous solution (30 mg / ml). Meloxicam is used intravenously in a hospital setting.

Most people usually take one tablet by mouth a day. If you miss a dose, take the missed dose as soon as you remember.However, if it’s almost time for your next dose, skip the missed dose and take your next dose as usual. Do not take a double dose. Meloxicam tablets should be stored at room temperature, out of the reach of children.

Many insurance plans cover meloxicam – 30-day delivery costs between $ 4 and over $ 400 (GoodRx, NA). The price depends on the strength and whether you buy branded or generic pills.

dry scaly skin on the shaft of the penis

Meloxicam drug interactions

Certain medicines may increase the risk of bleeding when taken with meloxicam.Since meloxicam reduces platelet function, blood thinners (such as warfarin), antiplatelet drugs (such as aspirin) should not be combined with meloxicam (DailyMed, 2019). Drinking alcohol while taking meloxicam also increases the risk of bleeding (FDA, 2012).

The combination of meloxicam with other NSAIDs (such as over-the-counter NSAIDs, naproxen, acetaminophen, or ibuprofen) increases the likelihood of developing gastrointestinal problems such as stomach bleeding or ulcers (DailyMed, 2019).

Meloxicam may reduce the effectiveness of other medicines. Meloxicam may produce drugs that lower high blood pressure (antihypertensive drugs), such as ACE inhibitors, angiotensin receptor blockers (ARBs), or beta blockers are less effective (Fournier, 2012; Johnson, 1994).

Meloxicam may also have this effect on diuretics (also known as water tablets), medications that reduce fluid retention. Loop diuretics such as furosemide and thiazide diuretics such as hydrochlorothiazide (HCTZ) may not work when taken with meloxicam (DailyMed, 2019).

Meloxicam can also increase the toxic effect of certain drugs on the kidneys. Taking meloxicam with these medicines, such as diuretics or cyclosporine, may increase the risk of side effects such as kidney problems. Combining these drugs can lead to kidney failure or even acute kidney failure. (FDA, 2012).

Meloxicam Warnings

Black Box Warning: Meloxicam may increase the risk of heart attacks and strokes, especially in people with heart disease or other cardiovascular risk factors.This risk may be higher if you take meloxicam for a long time. Do not use meloxicam to treat pain immediately before or after heart surgery, such as after a coronary artery bypass graft (CABG) procedure. Meloxicam may also increase the risk of gastrointestinal bleeding and ulcers or holes (perforations) in the stomach or intestines (FDA, 2012).

my penis is not completely hard

NSAIDs such as meloxicam should also not be taken during the third trimester of pregnancy.These medications can affect the development of the fetal heart and redirect blood flow in the fetal body, which can lead to progressive heart problems later on (Bloor, 2013; Enzensberger, 2012). If you are breastfeeding, tell your doctor before starting treatment with meloxicam.

Possible allergic reaction to meloxicam. You should not take this medicine if you are allergic to any of its ingredients. Call your doctor right away if you develop any signs of an allergic reaction, including severe skin reactions such as a rash with blisters or hives, shortness of breath, or swelling of the face.

How long does meloxicam last?

Although you may feel some relief during the first few days after starting treatment, it may take weeks or even months before you feel the full effect of meloxicam. One study found significant improvement in patients’ morning joint pain after three weeks of treatment (Reginster, 1996). Another study that examined the effects of meloxicam over 18 months found that patients reported increased relief during the first six months of the study.After six months, the improvement has stabilized (Huskisson, 1996).

Patients with osteoarthritis (OA) may experience a reduction in joint pain after two weeks of treatment. The researchers noted the evidence that meloxicam worked after just two weeks in patients receiving prescription drugs in daily doses of 7.5 or 15 mg. The results were also dose-dependent; those who received higher doses of meloxicam experienced greater relief (Yocum, 2000).

Recommendation

1. American College of Rheumatology (ACR) (2019).Gout. Retrieved September 16, 2020 from https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Gout
2. Bermas, B.L. (2014). Non-steroidal anti-inflammatory drugs, glucocorticoids, and disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis before and during pregnancy. Current opinion in rheumatology, 26 (3), 334-340. DOI: 10.1097 / bor.0000000000000054. Retrieved from https://pubmed.ncbi.nlm.nih.gov/24663106/
3. Bloor, M., and Paech, M. (2013). Non-steroidal anti-inflammatory drugs during pregnancy and lactation. Anesthesia and Pain Relief, 116 (5), 1063-1075. DOI: 10.1213 / ane.0b013e31828a4b54. Retrieved from https://pubmed.ncbi.nlm.nih.gov/23558845/
4. DailyMed (2019). Meloxicam tablet. Retrieved September 16, 2020 from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5e12448-1ca1-46a4-8de4-e8b94567e5a8
5. Encensberger K., Winhard J., Weichert J., Kavecki A., Degenhardt J., Vogel M. and Axt-Flidner R. (2012). Idiopathic narrowing of the fetal ductus arteriosus. Journal of Ultrasound in Medicine, 31 (8), 1285-1291. DOI: 10.7863 / jum.2012.31.8.1285. Retrieved from https://pubmed.ncbi.nlm.nih.gov/22837295/
6. Food and Drug Administration (FDA) (2012). Mobic (meloxicam) tablets and suspension for oral administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/012151s072lbl.pdf
7. Fournier, J.P., Sommet, A., Burrell, R., Oustrick, S., Patak, A., Lapeyre-Mestre, M., and Montastruck, J.L. (2012). Non-steroidal anti-inflammatory drugs (NSAIDs) and intensification of hypertension treatment: a population-based cohort study. European Journal of Clinical Pharmacology, 68 (11), 1533-1540. DOI: 10.1007 / s00228-012-1283-9. Retrieved from https://pubmed.ncbi.nlm.nih.gov/22527348/
8. Gaffo, A. L., MD, MsPH. (2019, December 4). Treatment of gout attacks. Retrieved September 18, 2020., from https://www.uptodate.com/contents/treatment-of-gout-flares/
9. GoodRx.com (undated). Meloxicam. Retrieved September 16, 2020 from https://www.goodrx.com/meloxicam
10. Huskisson, E.C., Ghozlan, R., Kurthen, R., Degner, F. L., & Bluhmki, E. (1996). Long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Rheumatology, 35 (Appendix 1), 29-34. Doi: 10.1093 / rheumatology / 35.suppl_1.29. Retrieved from https: // academic.oup.com/rheumatology/article/35/suppl_1/29/1782379
11. Jin, M., Yang, F., Yang, I., Yin, Y., Luo, J.J., Wang, H., and Yang, XF (2012). Uric acid, hyperuricemia, and vascular disease. The Frontiers of the Biological Sciences (Landmark Edition), 17, 656–669. DOI: 10.2741 / 3950. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247913/
12. Johnson, A.G., Nguyen, T.V., & Day, R .O. (1994). Do NSAIDs Affect Blood Pressure? Meta-analysis.Annals of Internal Medicine, 121 (4), 289-300. DOI: 10.7326 / 0003-4819-121-4-199408150-00011. Retrieved from https://pubmed.ncbi.nlm.nih.gov/8037411/
13. Martini, A.K., Rodriguez, K.M., Cap, A.P., Martini, V.Z., and Dubik , M.A. (2014). Acetaminophen and meloxicam inhibit platelet aggregation and coagulation in human blood samples. Clotting and fibrinolysis, 25 (8), 831-837. DOI: 10.1097 / mbc.0000000000000162. Retrieved from https://pubmed.ncbi.nlm.nih.gov/25004022/
14. National Institutes of Health (NIH).(2014, November 01). Symptoms and causes of peptic ulcers (stomach ulcers). Retrieved September 24, 2020, from https://www.niddk.nih.gov/health-information/digestive-diseases/peptic-ulcers-stomach-ulcers/symptoms-causes
15. National Institutes of Health (NIH). (2020, August 17). Ankylosing Spondylitis – Genetics Home Guide – NIH. Retrieved September 22, 2020, from https://ghr.nlm.nih.gov/condition/ankylosing-spondylitis
16. Reginster, J.Yu., Distel, M., and Bloomkey, E.(1996). A double-blind, three-week study comparing the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Rheumatology, 35 (Appendix 1), 17-21. Doi: 10.1093 / rheumatology / 35.suppl_1.17. Extracted from https://www.researchgate.net/profile/Erich_Bluhmki/publication/14569192_A_Double-Blind_Three-Week_Study_to_Compare_the_Efficacy_and_Safety_of_Meloxicam_75_mg_and_Meloxicam_15_mg_in_Patients_with_Rheumatoid_Arthritis/links/599d516745851574f4b258e4/A-Double-Blind-Three-Week-Study-to-Compare-the-Efficacy-and- Safety- of-Meloxicam-75-mg-and-Meloxicam-15-mg-in-Patients-with-Rheumatoid-Arthritis.pdf
17. Rinder, H.M., Tracy, J.B., Suhrada, M., Wang, K., Gagne, R.P., & Wood, C.S. (2002). Effect of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled study. Journal of Clinical Pharmacology, 42 (8), 881-886. DOI: 10.1177 / 009127002401102795. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12162470/
18. Yokum, D. (2000). Safety and efficacy of meloxicam in the treatment of osteoarthritis. Archives of Internal Medicine, 160 (19), 2947-2954.DOI: 10.1001 / archinte.160.19.2947. Retrieved from https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485487

Learn More

Medicines for Rheumatoid Arthritis Pain

If you have been diagnosed with rheumatoid arthritis, it is important to know about the types of pain relievers available.

One of the fundamental and, at the same time, the most obvious principle of rheumatoid arthritis treatment is overcoming pain.

There are many effective analgesics that your doctor can recommend. In contrast to PDBMs (basic anti-inflammatory drugs that modify the course of the disease), these drugs do not slow down joint erosion in rheumatoid arthritis. However, they help fight discomfort.

This is an overview of traditional pain relievers and anti-inflammatory drugs used in the treatment of rheumatoid arthritis.

Non-steroidal anti-inflammatory drugs (NSAIDs)

NSAIDs are the leading pain relievers used for rheumatoid arthritis.They are effective in relieving pain, swelling and stiffness. NSAIDs work by inhibiting the synthesis of specific enzymes (prostaglandins) that cause pain. They are classified into “selective” and “non-selective” depending on their action.

The following non-selective NSAIDs exist:

• Diclofenac (Voltaren, Cataflam)

• Etodolak (Lodin)

• Ibuprofen (Motrin, Advil)

• Indomethacin (Indocin)

• Meloxicam (Mobic)

• Naproxen (Aleve, Naprosin)

The main disadvantages of NSAIDs are their ability to cause ulcers and bleeding in the gastrointestinal tract.To reduce the risk of these complications, you should take a proton pump inhibitor, a drug that suppresses acid production in the stomach. NSAIDs can also cause stomach upset and general discomfort.

NSAIDs can cause complications if you have kidney failure or heart disease. Before you start taking NSAIDs, you need to tell your doctor about these conditions.

Selective NSAIDs (Celebrex, Arcoxia)

These drugs are classified as NSAIDs but have a lower risk of ulceration and gastrointestinal bleeding.They relieve pain as much as non-selective NSAIDs.

In 2004 and 2005, two selective NSAIDs, Viox and Bextra, were withdrawn from the market by manufacturers. The results of clinical studies have revealed an increased risk of heart attacks and strokes due to the use of these drugs. Celebrex, used in certain doses (200 milligrams daily), did not show such effects, and is still used for RA.

Selective NSAIDs are most suitable for individuals with a high incidence of gastrointestinal bleeding and requiring regular pain relievers.

Acetaminophen (Tylenol)

Acetaminophen is a common over-the-counter drug. Its main advantage is its safety of use. In appropriate doses, it causes a minimum of side effects in most people. The exception is people with liver complications, therefore, should take acetaminophen under the supervision of a doctor.

Corticosteroids

Corticosteroids are powerful drugs that stop inflammation.They differ from anabolic steroids such as testosterone, which promote muscle growth. Corticosteroids work throughout the body. In rheumatoid arthritis, the main benefit of corticosteroids is their ability to suppress overactive immune systems, alleviate symptoms, and slow the progression of the disease.

Because corticosteroids affect other body systems in addition to the immune system, they are more suitable for treating short-term outbreaks.This reduces the risk of side effects. If you have acute rheumatoid arthritis, you may need a longer course of corticosteroid treatment. During this course, your doctor will monitor the manifestation of side effects. Complications can include an increased susceptibility to infections, high blood sugar (diabetes), and thinning of bone tissue (osteoporosis).

Corticosteroids are sometimes injected directly into joints affected by rheumatoid arthritis.This is the best option for achieving a therapeutic effect with a low spectrum of side effects.

What you need to know about Mobic (meloxicam)

Mobic (meloxicam) is a prescription non-steroidal anti-inflammatory (NSAID) pain reliever approved for the treatment of certain types of arthritis. It reduces inflammation, which is the main cause of arthritis symptoms such as pain, stiffness, and swelling.

Mobic is available as a tablet or oral suspension (liquid), which is usually taken by mouth once a day.It is also available in generic form.

Meloxicam trademarks Qmiiz ODT and Vivlodex are specifically indicated for arthritis, while Anjescoan’s injectable meloxicam is indicated for moderate to severe pain not specific to arthritis; it is sometimes given along with oral NSAIDs to relieve arthritis pain.

Uses

Arthritis is a group of rheumatic diseases that cause joint inflammation and associated symptoms. Mobic reduces the production of inflammatory cells and proteins, which can reduce the inflammation and associated pain associated with arthritis.It is commonly prescribed for osteoarthritis, rheumatoid arthritis (RA), and juvenile idiopathic arthritis (JIA) .1

Osteoarthritis

The most common form of arthritis, osteoarthritis, is characterized by the destruction and thinning of cartilage in the joints. This process usually occurs due to normal wear and tear, which over time leads to an inflammatory response that causes joint swelling, pain and stiffness.

The joints of the knees, hips, hands, wrists, elbows and spine are most commonly affected.Mobic reduces joint pain and stiffness associated with osteoarthritis, but does not reduce the characteristic wear or damage to the joints.

Rheumatoid arthritis

RA is an autoimmune disease that occurs when the immune system attacks the joints. The inflammation causes swelling, pain, and joint stiffness. Over time, inflammation can damage and deform any of the joints in the body.

Juvenile idiopathic arthritis

A condition formerly called juvenile rheumatoid arthritis (JRA), JIA begins before the age of 16.JIA is an autoimmune disease that causes pain, stiffness, and swelling in the joints. It can also be associated with rashes, eye inflammation, fatigue, internal inflammation, and growth problems.

Mobic is used to treat oligoarthritis (four or fewer joints are affected) or polyarthritis (five or more joints are affected) forms of JIA in children 2 years of age or older.

Mobic may delay or reduce joint damage from RA and JIA, but does not slow the progression of these autoimmune diseases.

Outside label use

Meloxicam may also be off-label for other types of inflammatory conditions and pain, including fibromyalgia, tendonitis, and dysmenorrhea (menstrual cramps).

Before reception

A doctor may prescribe Mobic as a second-line treatment after lifestyle changes (such as diet and exercise) and common over-the-counter pain relievers (such as acetaminophen or lower-dose NSAIDs) have failed to provide sufficient symptom relief.

If you are considering getting meloxicam, your doctor will determine if Mobic is the best form for you or if an alternative brand is better for you.

For example, because Qmiiz ODT is a fast dissolving tablet that disintegrates in the mouth, it may be better suited for those who prefer this delivery method or have trouble swallowing drugs.

If side effects are of particular concern in patients with osteoarthritis, Vivlodex allows patients to start with a lower starting dose than Mobic.

Precautions and contraindications

Because Mobic can have serious and life-threatening side effects, including cardiovascular and gastrointestinal risks, your doctor will want to review your complete medical history before prescribing it for you.

They may also check your blood pressure and blood tests to check cholesterol levels, kidney and liver function, for example, to assess if there may be additional risks associated with taking the medication.

Certain medical circumstances may increase the risk of Mobic or even prohibit its use, including:

• Allergic reactions or asthma: Do not take meloxicam if you are hypersensitive to meloxicam, or if you have experienced asthma, hives (hives), or allergic reactions after taking aspirin or other NSAIDs. Severe and sometimes fatal allergic reactions to NSAIDs can occur.

• Heart surgery pending: Do not take Mobic for pain before coronary artery bypass grafting (CABG) surgery.

• Cardiovascular disease: NSAIDs can increase the risk of heart attack or stroke. Tell your doctor if you have had a heart attack or stroke in the past; you have heart disease or a family history of heart disease; and if you smoke or have hypertension (high blood pressure), high cholesterol, or diabetes.

• Fluid retention and edema: NSAIDs can cause fluid retention and edema (edema) in some people. Tell your doctor if you have a history of swelling or congestive heart failure.

• Gastrointestinal ulcers or bleeding: NSAIDs can cause severe ulcers and bleeding or perforation (holes) in the stomach or intestines. Tell your doctor if you have a history of ulcers or gastrointestinal bleeding, have a bleeding disorder, are taking oral corticosteroids, anticoagulants (blood thinners), or other NSAIDs that may increase this risk.

• Effects on kidneys or advanced kidney disease: Long-term use of NSAIDs can cause kidney damage.Tell your doctor if you have kidney disease, are on dialysis, or are taking diuretics or ACE inhibitors, which may increase your risk to your kidneys. Do not take meloxicam if you have advanced kidney disease.

• Effects on the liver: NSAIDs can cause elevated liver function tests or, in rare cases, severe liver reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure. Tell your doctor if you have liver dysfunction or any abnormal liver tests.

• Skin reactions: NSAIDs can cause serious skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be fatal. Tell your doctor if you have a history of skin reactions.

• Pregnancy: There are no adequately controlled studies of Mobic during pregnancy, but it crosses the placental barrier, posing risks to the developing fetus.Avoid taking NSAIDs after 30 weeks of pregnancy as they can cause premature closure of the fetal ductus arteriosus, a blood vessel that connects major arteries before birth.

• Breastfeeding. Those who are breastfeeding may not want to take Mobic as it can be passed on to the baby through breast milk.

• Those trying to get pregnant: NSAIDs can delay ovulation. Those who have difficulty conceiving or are undergoing fertility treatments should avoid taking this drug.

The same is true for some drugs that can interact with Mobic and increase the risk of serious side effects. Your doctor will weigh the pros and cons of your medication regimen and may consider changing other prescriptions if you need to take Mobic.

Medicines that can interact with Mobic include: 4

• Angiotensin-converting enzyme (ACE) inhibitors: Mobic may reduce the antihypertensive effect of these drugs.

• Blood thinning medications such as Jantoven or Coumadin (warfarin): Both warfarin and meloxicam carry a serious risk of gastrointestinal bleeding and other bleeding problems, which is increased when taken with Mobic.

• Rheumatrex or Trexall (methotrexate): Mobic may reduce the elimination of methotrexate from the body, increasing the risk of toxicity.

• Sandimmune (cyclosporine): Mobic may increase Sandimmune renal toxicity.

• Diflunisal or salsalate (salicylates): Mobic may increase the risk of gastrointestinal toxicity when taken with this drug.

• Pemetrexed: When taken simultaneously with the chemotherapy drug Pemetrexed Mobic, it may cause renal and gastrointestinal toxicity and decreased bone marrow activity.

• Kayexalate (sodium polystyrene sulfonate): Do not use Mobic Oral Suspension with Kayexalate.Sorbitol in oral suspension in combination with cayexalate may increase the risk of intestinal necrosis, a destruction of intestinal tissue that can be fatal.

Talk to your doctor about all medications, supplements, and vitamins you are currently taking. While some drugs pose a minor risk of interaction, others may directly contraindicate their use or prompt careful consideration of whether the benefits of treatment outweigh the disadvantages in your case.

Dosage

Mobic tablets are available in 7.5 and 15 milligrams (mg). The oral suspension is available at 7.5 mg per 5 milliliters (ml). Due to possible side effects, it is recommended to take Mobic at the lowest effective daily dose and for as short a period of time as possible.

For adults, start with 7.5 mg per day, and increase to 15 mg per day if necessary. The recommended dose for children is 0.125 mg per kilogram (kg) once a day, but not more than 7.5 mg.

All indicated dosages are indicated by the manufacturer of the drug. Check your prescription and talk to your doctor to make sure you are taking the correct dose. Never increase your dose without your doctor’s approval.

How to take and store

Mobic can be taken with or without food. If you have an upset stomach while taking it, you may want to adjust your dose with your meal. Shake the oral suspension well before use.

Mobic

should be stored at 77 degrees Fahrenheit away from heat and moisture, but you can travel with it in temperatures between 59 and 86 degrees Fahrenheit.Store tablets in a tight container and keep the container of the oral suspension tightly closed. As with all medicines, keep it out of the reach of children.

If you miss a dose, take it as soon as you remember; but if it’s close to your next dose, just skip the missed dose.

Signs of overdose

Call your doctor and get immediate medical attention if you have taken more than the prescribed dose of Mobic and have signs of an overdose, including:

• Drowsiness, lethargy

• Nausea, vomiting

• Pain under the ribs or in the upper abdomen

A large overdose can have more serious consequences such as breathing problems, coma, convulsions and heart attack.

Side effects

Like all medicines, meloxicam has a risk of side effects. Since some of these can be serious, it is important to be aware of them when you start taking the drug.

General

Common side effects include:

• Upset stomach

Serious

Serious and life-threatening side effects can occur with this medication, such as allergic reactions, heart attack or stroke, bleeding and stomach ulcers, and kidney or liver failure.

Get immediate medical attention if you have any of the following symptoms while taking Mobic: 5

• Severe stomach upset or pain

• Black or tarry stools

• High blood pressure

• Chest or back pain

• Weakness, falling

• Speech problems or confusion

• Asthma, hives, shortness of breath or other allergic reactions

• Flu-like symptoms

• Nausea or vomiting

• Loss of appetite

• Yellowing of the skin or eyes

• Dark or decreased urine output

Delayed body fluids and swelling

• Skin peeling or itching

• Severe dehydration

Abnormal liver function tests or kidney tests can also be a sign of a serious complication.

Alerts and interactions

While you are taking Mobic, your doctor may ask you to see you periodically to monitor blood pressure, liver and kidney function, and have blood tests to check for anemia, a possible complication of long-term NSAID use.

There are also drug interactions that may increase the risk of certain side effects or require your doctor’s supervision. Drug interactions may include:

• Aspirin: Taking these medicines together may increase the risk of side effects and complications such as gastrointestinal ulcers.

• Lithobide (lithium): Mobic can increase the concentration of lithium, therefore patients taking both drugs should be monitored for lithium toxicity.

• Diuretics such as Lasix (furosemide) or thiazide: Some of the effects of diuretics may be reduced in people taking Mobic and patients taking both drugs should be monitored for signs of renal failure.

Frequent alcohol consumption may increase the risk of side effects, which is why you should avoid it while taking Mobic.

Word from Verywell

Osteoarthritis, rheumatoid arthritis and juvenile idiopathic arthritis are chronic conditions. Your symptoms may increase or decrease, and you may be able to reduce your medication dose for months or even years at a time.

If you have arthritis, it is important to stay active and participate in therapy if your doctor recommends, because muscle stiffness can lead to inactivity, which worsens pain and overall health.Most people with arthritis can lead an active and productive life with the right treatment.

90,000 Alcohol and Arthritis Medications – Health

Many people taking arthritis medications are not sure if they can drink alcohol. Others do not even think that this is a rash combination. People tend to think I’m touching warnings

Contents

Many people on arthritis medications are unsure if they can drink alcohol.Others do not even think that this is a rash combination.

People tend to think that warnings concern everyone but themselves. It’s hard to imagine yourself in need of warning, error prone, or mortal. Maybe it’s just human nature. Sometimes we need strong reminders, and unfortunately, tragic events often deliver these reminders. Too often, a reminder comes after the death of a famous person due to an overdose. But it doesn’t have to be news to remind us.This information is attached to every prescription bottle we get from the pharmacy.

Each prescription bottle has tiny stickers attached to indicate correct use or warn of hazards. Although the stickers or labels may be small, their message should not be overlooked or ignored. When was the last time you noticed these little stickers? Check your recipes. Depending on the specific drug, you will see something like this:

Caution: Do not use with alcohol or over-the-counter medicines without the advice of a healthcare professional.

Do not drink alcohol while taking this medicine.

I would say the warnings are mostly clear. Why do I say basically ? Some people are still confused about how literal these warnings should be. So let’s get this clear once and for all. People with chronic conditions like arthritis usually take several different medications. A review of medications commonly used by people with arthritis provides the following information about alcohol consumption while taking medications.

NSAIDs (non-steroidal anti-inflammatory drugs)

NSAIDs include, but are not limited to, motrin (ibuprofen), naprosyn (naproxen), celebrex (celecoxib), and mobic (meloxicam). NSAIDs can cause bleeding or ulcers in the stomach or intestines. These problems can occur at any time during treatment, can occur without warning symptoms, and can lead to death. The risk may be higher for people who take NSAIDs for a long time, the elderly, those in poor health, or those who consume three or more alcoholic beverages per day while taking NSAIDs.Simply put, the likelihood of developing ulcers or bleeding increases with alcohol consumption.

Acetaminophen (brand name Tylenol)

Acetaminophen is used as monotherapy or also as an ingredient in some pain relievers such as Vicodin. There is an increased risk of acute liver failure in patients taking high doses of acetaminophen for a long time, or among those who consume alcohol.

DMARDs (disease-modifying antirheumatic drugs)

DMARDs include methotrexate and arava (leflunomide), azulfidine (sulfasalazine and plaquenil (hydroxychloroquine).Patients taking methotrexate are advised to avoid drinking alcohol, including beer, wine, and spirits, due to the increased risk of liver disease. Some Doctors Suppose that the occasional holiday drink (for example, on a birthday or on other special occasions) may not be harmful, but only abstinence is 100% guaranteed to be harmless.

Corticosteroids (eg, prednisone)

Corticosteroids may cause gastric bleeding. Drinking alcohol while taking steroids can increase your risk of stomach bleeding.

People with arthritis may also be prescribed sleeping pills, antidepressants, or muscle relaxants. These drugs, when combined with alcohol, can also have serious consequences.

Bottom Line

Medicines used to treat arthritis have risks of their own, primarily affecting the stomach, intestines or liver. Alcohol increases these risks. Discuss this issue with your doctor and pharmacist to understand why drinking alcohol is not recommended while taking your arthritis medication.

• Share
• Roll
• Email address
• Text

90,000 Porous tablets as carriers for liquid compositions

1. A chargeable tablet having a porosity of 30 v / v% or more for use as a pharmaceutical carrier composition for a pharmaceutically acceptable liquid composition comprising at least 50 w / v wt% pharmaceutically acceptable porosity-providing excipients selected from metal silicates and having a hardness of at least 20 N.

2. A chargeable tablet according to claim 1, comprising one or more pharmaceutically acceptable porosity-providing excipients which, when formulated into tablets, together with at most 50 w / w% lactose, provide a tablet having a porosity of 30 vol.% or more.

3. A chargeable tablet according to claim 2, wherein one or more porosity-enhancing excipients are present in the tablet at a concentration of about 50 w / w% or more.

4. A chargeable tablet according to claim 3, wherein the one or more porosity-providing excipients provide a tablet that has a porosity of 30 vol% or more and is present in the tablet at a concentration of about 60 w / w% or more, such such as about 70 w / w% or more, about 80 w / w% or more, about 90 w / w% or more, or about 95 w / w% or more.

5. Loaded tablet according to any one of paragraphs.2-4, wherein one or more porosity-providing excipients provide a tablet that has a porosity of 30 vol% or more and has a specific surface area (BET surface area) of at least 50 m ² / g as measured by gas adsorption.

6. A loaded tablet according to any one of the preceding claims, wherein the tablet, when placed in corn oil for 24 hours, has a tablet loading of at least 20 w / w%, such as, for example, at least 25 w / w./ wt% or at least 30 wt / wt% corn oil (based on the total weight of the solid dosage form after loading).

7. A chargeable tablet according to any one of the preceding claims, wherein the tablet has a hardness of about 35 N or more, about 40 N or more, about 45 N or more, or about 50 N or more.

8. A loadable tablet according to any one of the preceding claims, which has a friability of about 5% or less, such as, for example, about 4% or less, about 3% or less, about 2% or less, about 1% or less.

9. A loading tablet according to any one of claims 2 to 8, wherein the pharmaceutically acceptable excipient is a metal silicate selected from the group consisting of sodium silicate, potassium silicate, magnesium silicate, calcium silicate, including synthetic calcium silicate, zinc silicate , aluminum silicate, sodium aluminosilicate, magnesium aluminum silicate, magnesium aluminum metasilicate, aluminum metasilicate, neusilin SG2, neusilin US2, and mixtures thereof.

10. Loaded tablet according to any one of paragraphs.2-9, wherein the metal silicate is a swellable smectite-type clay selected from the group consisting of bentonite, vegum, and laponite.

11. A chargeable tablet according to any one of claims 2 to 10, wherein the metal silicate is selected from alkaline earth metal silicates and aluminum silicates including magnesium aluminum metasilicate.

12. A feed tablet according to any one of claims 9 to 11, wherein the metal silicate is neusilin.

13. A loading tablet according to any of the preceding claims, which is therapeutically inert.

14. A chargeable tablet according to claim 13, consisting of one or more inert pharmaceutically acceptable excipients.

15. A tablet as defined in any one of claims 1 to 14 loaded with a pharmaceutically acceptable liquid composition at a concentration of about 20 w / w% or more, such as, for example, about 25 w / w% or more, or about 30 w / w% or more (based on the total weight of the solid dosage form after loading).

16. The tablet according to claim15, wherein the pharmaceutically acceptable liquid composition is present at a concentration of about 40 w / w% or more, such as, for example, about 50 w / w% or more, or about 60 w / w% or more (based on on the total weight of the solid dosage form after loading).

17. A tablet according to claim 15 or 16, wherein the pharmaceutically acceptable liquid composition has a viscosity of at most about 600 mPa / s at a temperature of at most about 150 ° C.

18.A tablet according to any one of claims 15-17, wherein the pharmaceutically acceptable liquid composition has a melting point of at least about 0 ° C and at most about 250 ° C.

19. The tablet of claim 18, wherein the pharmaceutically acceptable liquid composition has a melting point of about 5 ° C or more, such as, for example, about 10 ° C or more, about 15 ° C or more, about 20 ° C or more or about 25 ° C or more.

20. Tablet according to any one of paragraphs.15-19, wherein the pharmaceutically acceptable liquid composition comprises an oil or oil-like substance.

21. A tablet according to any one of claims 15 to 20, wherein the pharmaceutically acceptable liquid composition comprises a pharmaceutically acceptable solvent.

22. A tablet according to claim 20, wherein the oil or oil-like substance is selected from the group consisting of vegetable oils, hydrogenated vegetable oils and animal oils.

23. A tablet according to claim 22, wherein the oil or oil-like substance is selected from the group consisting of apricot oil, almond oil, avocado oil, castor oil, coconut oil, cocoa butter, corn oil, cottonseed oil, grape oil, butter jojoba, linseed oil, maize oil, olive oil, palm oil, peanut oil, peach oil, poppy seed oil, rapeseed oil, sesame oil, soybean oil, sunflower oil, artichoke seed oil, nut oil, wheat germ oil, beef tallow, lard, tall oil, whale oil and mixtures thereof.

24. A tablet according to claim 22, wherein the oil or oil-like substance is a hydrophilic oil or an oil-like substance selected from the group consisting of polyether glycols such as, for example, polyethylene glycols, polypropylene glycols; polyoxyethylene; polyoxypropylene; poloxamers and mixtures thereof, or it can be selected from the group consisting of xylitol, sorbitol, sodium potassium tartrate, sucrose tribgenate, glucose, rhamnose, lactitol, behenic acid, hydroquinone monomethyl ester, sodium acetate, ethyl fumarate, myristic acid, citric acid , gelucir 50/13, other types of gelucir such as, for example, gelucir 44/14, etc.d., gelucir 50/10, gelucir 62/05, sucroester 7, sucroester 11, sucroester 15, maltose, mannitol and mixtures thereof.

25. A tablet according to claim 22, wherein the oil or oil-like substance is a hydrophobic oil or an oil-like substance selected from the group consisting of saturated straight chain hydrocarbons, sorbitan esters, paraffins; fats and oils such as, for example, cocoa butter, beef tallow, lard, polyethylene glycol esters; higher fatty acids such as, for example, stearic acid, myristic acid, palmitic acid, higher alcohols such as, for example, cetanol, stearyl alcohol, low melting waxes, such as, for example, glyceryl monostearate, glyceryl monooleate, hydrogenated tall oil, myristyl alcohol, stearyl alcohol, substituted and / or unsubstituted monoglycerides, substituted and / or unsubstituted diglycerides, substituted and / or unsubstituted triglycerides, yellow beeswax, white beeswax, carnauba wax, castor wax, Japanese waxes, monoglyates; NVP polymers, PVP polymers, acrylic polymers or mixtures thereof.

26. The tablet of claim 22, wherein the oil or oil-like substance is polyethylene glycol having an average molecular weight in the range of about 400 to about 35,000, such as, for example, from about 800 to about 35,000, from about 1,000 to about 35,000, such as, for example, polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 3000, polyethylene glycol 4000, polyethylene glycol 5000, polyethylene glycol 6000, polyethylene glycol 7000, polyethylene glycol 8000, polyethylene glycol 9000, polyethylene glycol 10000, polyethylene glycol 15000, polyethylene glycol 35000 or polyethylene glycol.In some cases, polyethylene glycol having a molecular weight of about 35,000 to about 100,000 can be used.

27. The tablet of claim 22, wherein the oil or oil-like substance is polyethylene oxide having a molecular weight of about 2,000 to about 7,000,000, such as, for example, from about 2,000 to about 100,000, about 5,000 to about 75,000, about 10,000 to about 60,000, about 15,000 to about 50,000, about 20,000 to about 40,000, about 100,000 to about 7,000,000, such as, for example, about 100,000 to about 1,000,000, about 100,000 to about 600,000, about 100,000 to about 400,000, or about 100,000 to about 300,000.

28. A tablet according to claim 22, wherein the oil or oil-like substance is a poloxamer, such as, for example, poloxamer 188, poloxamer 237, poloxamer 338 or poloxamer 407, or other block copolymers of ethylene oxide and propylene oxide, such as the Pluronic series and / or Tetronic®, where suitable block copolymers of the Pluronic® series include polymers having a molecular weight of about 3000 or greater, such as, for example, about 4000 to about 20,000, and / or a Brookfield viscosity of about 200 to about 4000 cps , such as, for example, from about 250 to about 3000 cps, where suitable examples include Pluronic® F38, P65, P68LF, P75, F77, P84, P85, F87, F88, F98, P103, P104, P105, F108, P123 , F123, F127, 10R8, 17R8, 25R5, 25R8, etc.where suitable block copolymers of the Tetronic series include polymers having a molecular weight of about 8000 or greater, such as, for example, about 9000 to about 35000, and / or a Brookfield viscosity of about 500 to about 45000 cps , such as, for example, from about 600 to about 40,000 cps, with the viscosities given above being determined at 60 ° C for substances that are pastes at room temperature and at 77 ° C for substances that are solid at room temperature …

29. A tablet according to claim 22, wherein the oil or oil-like substance is a sorbitan ester, such as, for example, sorbitan diisostearate, sorbitan dioleate, sorbitan monolaurate, sorbitan monoisostearate, sorbitan monooleate, sorbitan monopalmitate, sorbitan sostevietolestearate sorbitan, sorbitan sesquistearate, sorbitan triisostearate, sorbitan trioleate, sorbitan tristearate, or mixtures thereof.

30. A tablet according to claim 22, wherein the oil or oil-like substance is a mixture of various oils or oil-like substances, such as, for example, a mixture of hydrophilic and / or hydrophobic substances.

31. A tablet according to claim 22, wherein the oil or oil-like substance is a solvent or semi-solid excipient like, for example, propylene glycol, polyglycolized glycerides, including gelucir 44/14, a complex of vegetable fatty substances including cocoa butter, carnauba wax, vegetable oils like, for example, almond oil, coconut oil, corn oil, cottonseed oil, sesame oil, soybean oil, olive oil, castor oil, palm oil, peanut oil, rapeseed oil, grape oil, etc.hydrogenated vegetable oils such as, for example, hydrogenated peanut oil, hydrogenated palm oil, hydrogenated cottonseed oil, hydrogenated soybean oil, hydrogenated castor oil, hydrogenated coconut oil; natural fatty substances of animal origin, including beeswax, lanolin, fatty alcohols, including cetyl, stearyl, lauric, myristic, palmitic, stearic fatty alcohols; esters including glycerol stearate, glycol stearate, ethyl oleate, isopropyl myristate; liquid transesterified semisynthetic glycerides, including miglycol 810/812; amide or alkanolamides of fatty acids, including ethanol stearamide, diethanolamide of fatty acids of coconut oil, esters of acetic acid and mono- and diglycerides, esters of citric acid and mono- and diglycerides, esters of lactic acid and mono- and di-glycerides, mono- and di-glycerides of polyglycerides fatty acids, polyglycerol polyricinoleate, propylene glycol and fatty acid esters, sorbitan monostearates, sorbitan tristearates, sodium stearoyl lactylates, calcium stearoyl lactylates, diacetyl tartaric acid and mono- and diglyceride esters, etc.

32. A tablet according to any one of claims 15 to 31, wherein the pharmaceutically acceptable liquid composition is a dispersion, including an emulsion, a microemulsion, such as a self-microemulsifying drug delivery system (SMEDDS), or a suspension.

33. A tablet according to any one of claims 15 to 32, wherein the concentration of the pharmaceutically acceptable liquid composition in the tablet is about 5 w / w% or more, such as, for example, about 10 w / w% or more, about 15 wt./ w / w% or more, about 20 w / w% or more, about 25 w / w% or more, about 30 w / w% or more, about 35 w / w% or more about 40 w / w% or more, about 45 w / w% or more, about 50 w / w% or more, about 60 w / w% or more, or about 70 w / w wt% or more.

34. A tablet according to any one of claims 15 to 33, further comprising one or more therapeutically, prophylactically and / or diagnostically active substances.

35. A tablet according to claim 34, wherein the active agent is dispersed in a pharmaceutically acceptable liquid composition.

36. A tablet according to claim 34, wherein the active agent is at least partially dissolved in a pharmaceutically acceptable liquid composition.

37. A tablet according to claim 34, wherein the active substance is at least partially present in amorphous form.

38. A tablet according to any one of claims 15 to 37 having a hardness of at least about 25 N.

39.A tablet according to any one of claims 15 to 38 in the form of tablets having a friability of at most about 5%, such as, for example, at most about 4%, at most about 3%, at most about 2%, at most about 1%, or at most about 0.5%.

40. A tablet according to any one of claims 15 to 39, having a disintegration time of at most 15 minutes, according to the test methods according to Ph. Eur.

41. A tablet according to any one of claims 34-40, wherein at least 75% of the therapeutically, prophylactic and / or diagnostically active substance is released after 30 minutes when tested by the dissolution method according to USP.

42. A method for preparing a tablet, comprising the following steps:

i) obtaining a downloadable tablet as defined in any one of claims 1-14, optionally comprising one or more therapeutically, prophylactically and / or diagnostically active substances,

ii) loading the loadable tablet obtained from step i) with a pharmaceutically acceptable liquid composition as defined in any one of claims 15 to 41, optionally comprising one or more therapeutically, prophylactically and / or diagnostically active substances, over a period of time, which is sufficient to saturate the loadable tablet with a pharmaceutically acceptable liquid composition.

43. The method of claim 42, wherein loading the loadable tablet with a pharmaceutically acceptable liquid composition, optionally including one or more therapeutically, prophylactically and / or diagnostically active substances, is carried out by spraying.

44. The method of claim 42, wherein loading the loading tablet with a pharmaceutically acceptable liquid composition, optionally including one or more therapeutically, prophylactically and / or diagnostically active substances, is performed by placing the loading tablet in an excess of the pharmaceutically acceptable liquid composition, optionally including itself one or more therapeutically, prophylactically and / or diagnostically active substances.

45. The method according to any one of claims 42 to 44, wherein the time period in step ii) is at most about 60 minutes, such as, for example, at most about 45 minutes, or at most about 30 minutes for the number of tablets loaded corresponding to 1 kg.

013632 FIELD OF THE INVENTION The present invention relates to a novel tablet product which can be loaded in an easy, adaptable and reproducible manner with a relatively large amount of a pharmaceutically acceptable liquid composition, for example, carrying a therapeutically, prophylactically and / or diagnostically active substance.The new tabletted product can be made in large scale batches and stored until use, and each batch or sub-batch can be loaded with the same or different pharmaceutically acceptable liquid compositions and / or actives. The invention also provides tablets that have been loaded with such a liquid composition, as well as a process for their preparation. The invention provides a method for the preparation of tablets comprising an active substance together with a suitable and relatively large amount of liquid, which affects the availability of the active substance, for example, for release and / or absorption upon oral administration.BACKGROUND OF THE INVENTION There are many drug substances and it is anticipated that many of the future drug substances will have undesirable properties, especially with regard to, for example, water solubility and oral bioavailability. Therefore, there is a great need for new technologies that make it possible to deliver to the body, especially therapeutically and / or prophylactically active substances, in a relatively easy way and at the same time make it possible to induce the required therapeutic and / or prophylactic response.In the pharmaceutical field, it is common to prepare pharmaceutical compositions comprising one or more active substances and various excipients. One of the reasons for the preparation of such pharmaceutical compositions is to influence the availability of the active compound after ingestion of the pharmaceutical composition. For the preparation of a pharmaceutical composition for oral administration, the active substances are often included in an agglomerated preparation to provide the active compounds in a form that can be compressed into tablets or filled into capsules.In addition to providing the active substance in a form that can be compressed into tablets, agglomerates can also be designed to provide the required availability of the active compound after ingestion of a pharmaceutical composition containing such a granule. Enhancing the oral bioavailability of poorly water-soluble drugs, as well as providing a sufficiently water-soluble drug in sustained release form, retains one of the most desirable aspects of drug development, and further development of agglomeration techniques can provide valuable means for these aspects.One of the commonly used granulation techniques is wet granulation, in which a mixture of powders containing the active compound is mixed with a liquid, usually an aqueous liquid, under mechanical action to form granules. Granules are usually prepared by wet granulation and dried before use. Melt agglomeration and controlled agglomeration are techniques for the agglomeration of an active compound, especially performed by melting a pharmaceutically acceptable excipient such as an oil or oil-like substance, dissolving or dispersing one or more active compounds in a molten excipient and depositing the mixture thus obtained on particles of material, filler, and then the adhesion of the particles to each other and the formation of agglomerates.WO 03/004001 (by the inventors) describes a novel controlled agglomeration technique in which a particulate material can be loaded with a relatively large amount of oil or oil-like substance. The technique is based on a technique that involves spraying a carrier composition containing an oil or oil-like substance onto a particulate material. The process conditions allow the particulate material to be loaded with a relatively large amount of oil or oil-like substance.Typically, the method includes heating the carrier composition and maintaining the temperature of the carrier composition during application. When spraying is applied, strict temperature control of the sprinkler is a requirement in order to avoid problems related to clogging of the spray nozzle, etc. SUMMARY OF THE INVENTION The present inventors have found a much simpler solution to the problem. They have found that it is possible to obtain a tablet containing only inert pharmaceutically acceptable excipients (although in some cases it may suitably include the active substance), and when the tablet is treated with a pharmaceutically acceptable liquid composition, for example containing the active substance, the tablet due to its porosity will suck in the liquid composition.Most surprisingly, such loading of the inert tablet occurs in a relatively short period of time and is reproducible, i. E. the same amount of liquid composition is sorbed when the same type and size of tablet and liquid composition is used (see examples provided herein). Until the best suggestions of the authors of the present invention, inert tablets with the above properties had not been previously developed or previously used in the pharmaceutical field for loading tablets with liquids, for example, containing an active substance.WO 00/38655 (Alza Corporation) describes a dosage form including porous particles. The dosage form can be in the form of tablets, which are prepared by mixing the porous particles with a liquid carrier such as propylene glycol. However, in contrast to the present invention, this document does not describe inert tablets that have the ability to adsorb a liquid active substance or a lipophilic medium containing one or more active substances in a reproducible manner and which allow a high liquid loading to be achieved.EP-A-0001247 relates to preparations of nifedipine for oral administration in the form of a solution of nifedipine in polyethylene glycol supported on a pharmaceutically acceptable porous carrier, or a non-crystalline dispersion of nifedipine in polyvinylpyrrolidone. Inert loading tablets are not described. US patent 6,399,591 (Yung-Shin Pharmaceutical Ind. Co. Ltd.) relates to unfilled tablets that include an absorbent, disintegrant, lubricant and diluent or binder, or a mixture of diluent and binder.The active ingredient in liquid form is incorporated into a blank tablet to prepare a pharmaceutical composition. However, the examples show that only about 13 w / w% feed can be obtained. The tablets of the present invention can be loaded with any type of active substance, and they can also be designed for any type of release of the active substance. The loading of inert tablets depends on the type and nature of the pharmaceutically acceptable excipients that are contained in the tablet. A critical parameter, however, is not only the properties of the pharmaceutically acceptable excipients contained in the tablet, but also the properties of the tablet itself.In this regard, the most critical properties are the tablet’s ability to i) sorb the pharmaceutically acceptable liquid composition in sufficient quantity, ii) maintain the sorbed amount during storage without any evaporation of the liquid composition from the tablet surface, and iii) release the active substance when the tablet is exposed in vitro dissolution test and / or is administered orally to a subject, such as an animal, including a human. To meet these requirements, the present inventors have found that a critical property of the tablets to be loaded is the porosity of the tablet.Accordingly, in one aspect, the present invention provides a downloadable tablet having a porosity of 30 v / v% or greater as a pharmaceutical carrier composition for a pharmaceutically acceptable liquid composition. Conventional tablets used in the pharmaceutical field have a porosity that is much lower. One of the reasons why very porous tablets are avoided is that such tablets are not strong enough to allow normal handling of the tablets during packaging and storage, i.e.That is, they do not meet the requirements of the pharmacopoeia in terms of hardness and brittleness. Porosity is defined as the ratio of the volume between the voids in the tablet and the total volume of the tablet according to Equation 1 in the examples provided herein. Downloadable tablets In the present context, the term inert tablet is used to mean a tablet that contains only ingredients that are generally considered to be inert with respect to therapeutic action. More specifically, such a tablet contains pharmaceutically acceptable excipients selected from the group consisting of fillers, diluents, binders, lubricants, glidants, etc.and additives such as pH adjusting agents, buffering agents, active substance enhancers, wetting agents, solubilizing agents, surfactants, antioxidants, etc. The term loadable tablet as used in the present context means an inert tablet as defined above, but additionally having a porosity of at least 30 v / v% to allow suitable liquid loading. However, in some cases it may be interesting to include the active substance in such a tablet and, accordingly, the term downloadable tablet also includes such cases.In a preferred embodiment, the tablets are inert and loadable, i. E. without any active substance content before loading. However, as shown here in the examples, the present inventors have found that tablets having a high porosity can be loaded with a pharmaceutically acceptable liquid, preferably containing one or more therapeutically, prophylactically and / or diagnostically active substances (hereinafter abbreviated as active substance).The loaded tablets are strong enough to withstand normal tablet handling during further processing (eg coating), packaging, storage, etc., i. E. they meet the requirements of the pharmacopoeia in terms of hardness and brittleness. In a specific embodiment, a loaded tablet according to the invention is obtained when tested as described herein at a tablet loading of at least 20 w / w%, such as, for example, at least 25 w / w./ wt% or at least 30 wt / wt% corn oil (based on the total weight of the solid dosage form after loading). This test ensures, -2 013632, that the tablet has the ability to absorb a liquid composition that is suitable for use in the preparation of tablets. As indicated above, the loadable tablets of the invention are strong enough to withstand normal tablet handling, i. E. they have a hardness of 20 N or more, such as, for example, about 25 N or more, about 30 N or more, about 35 N or more, about 40 N or more, about 45 N or more, or about 50 N or more.In addition, the tablets of the invention have a friability of about 5% or less, such as, for example, about 4% or less, about 3% or less, about 2% or less, such as about 1% or less. As indicated above, the loading tablets of the invention comprise one or more pharmaceutically acceptable excipients. However, it is important that at least one pharmaceutically acceptable excipient has suitable properties to provide a tablet with a porosity of 30 vol./ vol% or more and that this excipient is present in a sufficient amount so that the resulting tablet also has the required porosity. Such pharmaceutically acceptable excipients are sometimes referred to herein as pharmaceutically acceptable porosity-providing excipients. In this regard, the present inventors have found that when a pharmaceutically acceptable excipient is formulated as tablets together with at most 50 w / w% lactose or other pharmaceutically acceptable excipients used for direct compression, such as, for example, emcompress, and the resulting the tablets have a porosity of 30 vol.% or more, then a pharmaceutically acceptable excipient is suitable for use in the present context. The quality of the lactose is suitable for direct compression. In the loaded tablets, the sum of the pharmaceutically acceptable excipients which have the above properties (i.e., satisfy the above test) corresponds to at least 50 w / w%, such as, for example, at least 55 w / w. %, at least 60 w / w%, at least 65 w / w%, at least 70 w / w./ w / w%, at least 80 w / w%, at least 90 w / w%, at least 95 w / w%, or at least 98 w / w%, such such as 100 w / w% of the total weight of the tablet. In preferred aspects, one or more porosity-providing excipients are present in the tablet at a concentration of about 50 w / w% or more, such as, for example, about 60 w / w% or more, such as, for example, about 70 w / w. / wt% or more, about 80 wt./ w / w% or more, about 90 w / w% or more, or about 95 w / w% or more. In addition, it is contemplated that the specific surface area (BET surface area) of the porosity-providing excipient should be relatively high, such as, for example, at least 50 m 2 / g, as measured by gas absorption. The following is a list of pharmaceutically acceptable excipients that have suitable properties to provide a loadable tablet according to the invention.Individual pharmaceutically acceptable excipients can be used singly or in combination, provided that the overall goal of porosity is achieved. In this regard, it should be noted that tablets are compressed into tablets using a certain compression force. However, the pressing force cannot be too low so that the requirements for hardness and brittleness are deteriorated, i. E. these requirements ensure that the tablets are strong enough. Suitable pharmaceutically acceptable excipients that can be used to prepare tablets having a porosity of 30 vol./ vol% or more, selected from metal silicates. The metal is usually selected from the group consisting of sodium, potassium, magnesium, calcium, zinc, aluminum, titanium, and silicon. Silicates can be divided into the following groups: Swelling clays of the smectite type, for example bentonite, veegum, laponite; Hydrous silicates of aluminum or alkaline earth metals. Neusilin belongs to this group and is based on synthetic polymerization (magnesium-aluminum metasilicate). Silicon dioxides are subdivided into porous and non-porous silicas: non-porous colloidal silicas, for example aerosil (colloidal silicas), gels of porous silicon dioxides, for example siloid, porosil, lychrosorp, others, for example, Zeopharm S 300170, aeropharm.In other embodiments, the pharmaceutically acceptable excipient for use according to the invention is a metal silicate selected from the group consisting of sodium silicate, potassium silicate, magnesium silicate, calcium silicate, including synthetic calcium silicate such as, for example, gubersorp, zinc silicate, aluminum silicate , sodium aluminosilicate such as, for example, zeolex, magnesium aluminum silicate, magnesium aluminum metasilicate, aluminum metasilicate, neusilin SG2 and neusilin US2, and mixtures thereof.The metal silicate may also be a swellable smectite-type clay selected from the group co-3 013632 consisting of bentonite, vegum and laponite, and / or the metal silicate selected from alkaline earth metal silicates and aluminum silicates, including magnesium aluminum metasilicate. In a specific embodiment, the metal silicate is neusilin. Other pharmaceutically acceptable excipients for use in a loading tablet according to the invention. The loaded tablet may, of course, contain other pharmaceutically acceptable excipients, such as pharmaceutically acceptable excipients commonly used in the manufacture of tablets.In the present context, the term pharmaceutically acceptable excipient is intended to mean any substance that is inert in the sense that it essentially has no therapeutic and / or prophylactic effect per se. Such an excipient can be added to make it possible to obtain a pharmaceutical, cosmetic and / or food composition that has acceptable technical properties. Examples of suitable excipients for use in a loading tablet according to the invention include fillers, diluents, disintegrants, binders, lubricants, etc.etc. or mixtures thereof. Since the composition or solid dosage form according to the invention can be used for different purposes, the choice of excipients usually forces such different applications to be taken into account. Other pharmaceutically acceptable excipients for suitable use are, for example, acidifying agents, alkalizing agents, preservatives, antioxidants, buffering agents, chelating agents, coloring agents, complexing agents, emulsifying and / or solubilizing agents, flavors and fragrances, moisturizing agents, sweetening agents agents, etc.e. Examples of suitable fillers, diluents, and / or binders include lactose (e.g. spray dried lactose, β-lactose, β-lactose, tabletose, various varieties of pharmacoses, microtoses, or fast-flock), microcrystalline cellulose (various varieties of Avicel, Elcema, Vivacel , Ming Thai or Salka-flock), hydroxypropyl cellulose, L hydroxypropyl cellulose (weakly substituted), hydroxypropyl methyl cellulose (HPMC) (e.g. methocel E, F and K, Shin-Etsu Ltd SH Metolose, such as, for example, Metolose E and Metolose 60 SH with a viscosity of 4000 cP, Metolose F and Metolose 65 SH grades with a viscosity of 4000 cP, Metolose K grades with viscosities of 4000, 15000 and 100000 cP and Metolose 90 SH grades with viscosities of 4000, 15000, 39000 and 100000 cP), methylcellulose polymers (such as , for example, methocel A, methocel A 4 C, methocel A 15 C, methocel A 4 M), hydroxyethyl cellulose, sodium carboxymethyl cellulose, carboxymethylene, carboxymethyl hydroxyethyl cellulose and other cellulose derivatives, sucrose, agarose y, sorbitol, mannitol, dextrins, maltodextrins, starches or modified starches (including potato starch, maize starch and rice starch), calcium phosphate (eg basic calcium phosphate, calcium hydrogen phosphate, dicalcium phosphate hydrate), calcium sulfate, calcium carbonate, sodium alginate , collagen, etc.e. Specific examples of diluents are, for example, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrans, dextrin, dextrose, fructose, kaolin, lactose, mannitol, sorbitol, starch, pregelatinized starch , sucrose, sugar, etc. Specific examples of disintegrants are, for example, alginic acid or alginates, microcrystalline cellulose, hydroxypropyl cellulose and other cellulose derivatives, croscarmellose sodium salt, crospovidone, polacrillin potassium salt, sodium starch glycolate, starch, pre-gelatinized carboximetric starch and exported starch etc.Specific examples of binders are, for example, gum arabic, alginic acid, agar, carrageenan calcium salt, sodium carboxymethyl cellulose, microcrystalline cellulose, dextrin, ethyl cellulose, gelatin, liquid glucose, guar gum, hydroxypropyl methylcellulose, peptide , pregelatinized starch, etc. Glidants and lubricants may also be included in the tablets. Examples include stearic acid, magnesium stearate, calcium stearate or other metal stearate, talc, waxes and glycerides, light mineral oil, PEG, glyceryl behenate, colloidal silicon dioxide, hydrogenated vegetable oils, corn starch, sodium stearyl fumarate, sodium polyethylene glycolate, sodium polyethylene glycolate , sodium acetate, etc.Other excipients that can be included in the loading tablet of the invention are, for example, flavoring agents, coloring agents, taste masking agents, pH adjusting agents, buffering agents, preservatives, stabilizing agents, antioxidants, wetting agents, moisture adjusting agents, surfactants, suspending agents, absorption enhancing agents, modified release agents, etc.-4 013632 Other additives to the composition or solid dosage form according to the invention may be antioxidants like, for example, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerin, potassium metabisulfite, propyl gallate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium thiosulfate, sulfur dioxide, tocopherol, tocopherol acetate, tocopherol hemisuccinate tocopherol and other derivatives of tocopherol tocopherol tocopherol and other derivatives of tocopherol tocopherol.e. The carrier composition may also contain, for example, stabilizing agents. The concentration of the antioxidant and / or stabilizing agent in the carrier composition is typically from about 0.1 w / w% to about 5 w / w%. The composition or solid dosage form according to the invention may also include one or more surfactants or substances with surfactant properties. It is believed that such substances take part in the wetting of the poorly soluble active substance and, thus, contribute to the improvement of the solubility characteristics of the active substance.The following are examples of surfactants. Suitable excipients for use in the tablet according to the invention are surfactants such as, for example, amphiphilic surfactants such as those described in W0 00/50007 in the name of Lipocine, Inc. Examples of suitable surfactants are: i) polyethoxylated fatty acids, such as, for example, mono- or diesters of fatty acids and polyethylene glycol or mixtures thereof, such as, for example, mono- or diesters of polyethylene glycol with lauric acid, oleic acid, stearic acid , myristic acid, ricinoleic acid, where the polyethylene glycol can be selected from PEG 4, PEG 5, PEG 6, PEG 7, PEG 8, PEG 9, PEG 10, PEG 12, PEG 15, PEG 20, PEG 25, PEG 30, PEG 32, PEG 40, PEG 45, PEG 50, PEG 55, PEG 100, PEG 200, PEG 400, PEG 600, PEG 800, PEG 1000, PEG 2000, PEG 3000, PEG 4000, PEG 5000, PEG 6000, PEG 7000, PEG 8000, PEG 9000, PEG 1000, PEG 10000, PEG 15000, PEG 20000, PEG 35000, (ii) polyethylene glycol and glycerin fatty acid esters, i.e.e. esters like the above, but in the form of glyceryl esters of individual fatty acids; (iii) esters of glycerin, propylene glycol, ethylene glycol, PEG or sorbitol, for example with vegetable oils like, for example, hydrogenated castor oil, almond oil, palm oil, castor oil, apricot oil, olive oil, peanut oil, hydrogenated palm oil and the like, (iv) polyglycerized fatty acids like, for example, polyglycerol stearate, polyglycerin oleate, polyglycerol ricinoleate, polyglycerol fatty linoleate, (v) polyglycerol fatty acids such as, for example, propylene glycol monolaurate, propylene glycol ricinoleate and the like, (vi) mono- and diglycerides like, for example, glyceryl monooleate, glyceryl dioleate, glyceryl mono- and / or -dioleate, glyceryl caprylate, glyceryl caprate and the like.(viii) polyethylene glycol sorbitan fatty acid esters (PEG sorbitan fatty acid esters) such as the various molecular weight PEG esters listed above and a number of different tweens; (ix) polyethylene glycol alkyl ethers such as, for example , PEG oleyl ether and PEG lauryl ether; (xi) ethers of polyethylene glycol and alkyl phenols, like, for example, triton of series X or N; xii) block copolymers of polyoxyethylene-polyoxypropylene, such as, for example, pluronic series, synperonic series, emcalix, lutrol, supronic, etc.The generic name for these polymers is poloxamer and suitable examples in the present context are poloxamer 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234 , 235, 237, 238, 282, 284,288, 331, 333, 334, 335, 338, 401, 402, 403 and 407; xiii) sorbitan fatty acid esters, like esters of the span or ariacel series, such as, for example, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monooleate, sorbitan monostearate, etc.; xiv) esters of lower alcohols and fatty acids, like, for example, oleate, isopropyl myristate, isopropyl palmitate, etc.xv) ionic surfactants, including cationic, anionic and zwitterionic surfactants such as, for example, fatty acid salts, bile salts, phospholipids, phosphoric acid esters, carboxylates, sulfates and sulfonates, etc. etc. When a surfactant or mixture of surfactants is present in a composition or solid dosage form of the invention, the concentration of surfactant substance (s) is typically in the range of about 0.1-80 wt./ wt%, such as, for example, from about 0.1 to about 20 w / w%, from about 0.1 to about 15 w / w%, from about 0.5 to about 10 wt. / wt%, or alternatively from about 0.10 to about 80 w / w%, such as, for example, from about 10 to about 70 w / w%, from about 20 to about 60 w / w / wt.% or from about 30 to about 50 wt./wt.%. Tablets Loaded with a Pharmaceutically Acceptable Liquid The tablets described above are designed so that they can be loaded with a pharmaceutically acceptable liquid composition at a concentration of about 20 wt./ wt% or more, such as, for example, about 25 w / w% or more, about 30 w / w% or more (based on the total weight of the solid dosage form after loading). Accordingly, in another aspect, the invention relates to such tablets. In preferred aspects, the pharmaceutically acceptable liquid composition is present at a concentration of about 40 w / w% or more, such as, for example, about 50 w / w% or more, or about 60 w / w.% or more (based on the total weight of the solid dosage form after loading). A critical parameter in connection with the loading of the liquid composition is the viscosity of the liquid composition. Loading can be done in any way possible, such as, for example, placing the tablets in a suitable container containing liquid, or spraying the liquid onto the tablets in a suitable apparatus such as, for example, a conventional coating device such as a coating pan, perforated vessel or fluidized bed.The viscosity of the liquid is particularly important when the liquid composition is sprayed onto tablets. Accordingly, in a particular embodiment, the pharmaceutically acceptable liquid composition has a viscosity of at most about 600 mPa / s at a temperature of at most about 150 C. In addition, the pharmaceutically acceptable liquid composition has a melting point of at least about 0 C and at most about 250 C, such as, for example, about 5 C or more, such as, for example, about 10 C or more, about 15 C or more, about 20 C or more, or about 25 C or more.The melting point is not very critical as the liquid composition can be heated or cooled in connection with loading the tablets with the liquid composition. The pharmaceutically acceptable liquid composition may be water based, or it may be based on an organic solvent or oil or an oil-like substance. Surprisingly, the inventors have found that the loading tablet according to the invention can be immersed in water and after saturation with water (which takes only a few minutes or less), the tablet appears to have a cold but dry surface, i.e.e. water and aqueous liquid can also be used with a suitable pharmaceutically acceptable liquid composition. However, a more general suitability was investigated with regard to loading tablets with active substances contained in an aqueous or organic liquid. Such liquids include oil or oily substances, or pharmaceutically acceptable solvents. Such oils or oil-like substances can be selected from the group consisting of water, vegetable oils, hydrogenated vegetable oils and animal oils.Suitable examples include apricot oil, almond oil, avocado oil, castor oil, coconut oil, cocoa butter, corn oil, cottonseed oil, grape oil, jojoba oil, linseed oil, maize oil, olive oil, palm oil, peanut oil, peach oil, poppy seed oil, rapeseed oil, sesame oil, soybean oil, sunflower oil, artichoke oil, nut oil, wheat germ oil, beef tallow, lard, tall oil, whale oil, and mixtures thereof. Other examples are hydrophilic oils or oil-like substances selected from the group consisting of polyether glycols such as, for example, polyethylene glycols, polypropylene glycols; polyoxyethylene; polyoxypropylene; poloxamers and mixtures thereof, or the oil can be selected from the group consisting of xylitol, sorbitol, sodium potassium tartrate, sucrose tribogenate, glucose, rhamnose, lactitol, behenic acid, hydroquinone monomethyl ester, sodium acetate, ethyl fumarate, myristic acid, citric acid , gelucir 50/13, other types of gelucir such as, for example, gelucir 44/14, etc.d., gelucir 50/10, gelucir 62/05, sucroester 7, sucroester 11, sucroester 15, maltose, mannitol and mixtures thereof. The oil or oil-like substance can also be a hydrophobic oil or an oil-like substance selected from the group consisting of straight chain saturated hydrocarbons, sorbitan esters, paraffins; fats and oils such as, for example, cocoa butter, beef tallow, lard, polyethylene glycol esters; higher fatty acids such as, for example, stearic acid, myristic acid, palmitic acid, higher alcohols such as cetanol, stearyl alcohol, low melting waxes, such as glyceryl monostearate, glyceryl monooleate, hydrogenated tall oil, , stearyl alcohol, substituted and / or unsubstituted monoglycerides, substituted and / or unsubstituted diglycerides, substituted and / or unsubstituted triglycerides, yellow beeswax, white beeswax, carnauba wax, castor wax, Japanese wax, acetylate monoglycerides; NVP polymers, PVP polymers, acrylic polymers or mixtures thereof.Suitable polyethylene glycols typically have an average molecular weight in the range of about 400 to about 35,000, such as, for example, about 800 to about 35,000, about 1,000 to about 35,000, such as, for example, polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 3000, polyethylene glycol 4000, polyethylene glycol 5000, polyethylene glycol 6000, polyethylene glycol 7000, polyethylene glycol 8000, polyethylene glycol 9000, polyethylene glycol 10000, polyethylene glycol 15000, polyethylene glycol 20,000 or polyethylene glycol 35000.In some cases, polyethylene glycol with a molecular weight of from about 35,000 to about 100,000 can be used. In a specific embodiment, the oil or oil-like substance can be polyethylene oxide having a molecular weight of from about 2,000 to about 7,000,000, such as, for example, from about 2,000 to about 100,000. about 5,000 to about 75,000, about 10,000 to about 60,000, about 15,000 to about 50,000, about 20,000 to about 40,000, about 100,000 to about 7,000,000, such as, for example, about 100,000 to about 1,000,000, about 100,000 to about 600,000, from about 100,000 to about 400,000, or from about 100,000 to about 300,000.Poloxamers can also be used according to the invention. Examples include poloxamer 188, poloxamer 237, poloxamer 338 or poloxamer 407, or other block copolymers of ethylene oxide and propylene oxide, such as the Pluronic and / or tetronic series. Suitable block copolymers of the Pluronic series include polymers having a molecular weight of about 3000 or greater, such as, for example, about 4000 to about 20,000, and / or a Brookfield viscosity of about 200 to about 4000 cps, such as, for example, from about 250 to about 3000 cps.Suitable examples include Pluronic F38, P 65, P68LF, P 75, F77, P 84, P 85, F87, F88, F98, P 103, P 104, P 105, F108, P 123, F123, F127, 10R8, 17R8, 25R5, 25R8, etc. Suitable tetronic block copolymers include polymers having a molecular weight of about 8,000 or greater, such as, for example, about 9,000 to about 35,000, and / or a Brookfield viscosity of about 500 to about 45,000 cps, such as, for example, about 600 to approximately 40,000 cp.The viscosities given above are determined at 60 ° C for substances that are pastes at room temperature and at 77 ° C for substances that are solid at room temperature. In another embodiment, the oil or oil-like substance can be a sorbitan ester, such as, for example, sorbitan diisostearate, sorbitan dioleate, sorbitan monolaurate, sorbitan monoisostearate, sorbitan mono-oleate, sorbitan monopalmitate, sorbitan triostearate, sorbitan sorbitan isostearate, sorbitan sorbitisostearate sorbitan, sorbitan trioleate, sorbitan tristearate, or mixtures thereof.In addition or alternatively, the oil or oil-like substance can be a mixture of different oils or oil-like substances, such as, for example, a mixture of hydrophilic and / or hydrophobic substances, or a solvent or semi-solid excipient, like, for example, propylene glycol, polyglycolized glycerides, including gelucir 44 / 14, a complex of vegetable fatty substances, including cocoa butter, carnauba wax, vegetable oils like, for example, almond oil, coconut oil, corn oil, cottonseed oil, sesame oil, soybean oil, olive oil, castor oil, palm oil , peanut butter, rapeseed oil, grape seed oil, etc.hydrogenated vegetable oils such as, for example, hydrogenated peanut oil, hydrogenated palm oil, hydrogenated cottonseed oil, hydrogenated soybean oil, hydrogenated castor oil, hydrogenated coconut oil; natural fatty substances of animal origin, including beeswax, lanolin, fatty alcohols, including cetyl, stearyl, lauric, myristic, palmitic, stearic fatty alcohols; esters including glycerol stearate, glycol stearate, ethyl oleate, isopropyl myristate; liquid transesterified semisynthetic glycerides, including miglycol 810/812; amide or alkanolamides of fatty acids, including ethanol stearamide, diethanolamide of fatty acids of coconut oil, esters of acetic acid and mono- and diglycerides, esters of citric acid and mono- and diglycerides, esters of lactic acid and mono- and diglycerides, mono- and diglycerides of polyglycerides fatty acids, polyglycerol polyricinoleate, propylene glycol and fatty acid esters, sorbitan monostearates, sorbitan tristearates, sodium stearoyl lactylates, calcium stearoyl lactylates, diacetyl tartaric acid esters and mono- and diglycerides-7 013632, etc.e. The pharmaceutically acceptable liquid composition can also be a dispersion, including an emulsion, a microemulsion, for example, a self-microemulative drug delivery system (SMEDDS), or a suspension. The concentration of the pharmaceutically acceptable liquid composition in the tablet is typically about 5 w / w% or more, such as, for example, about 10 w / w% or more, about 15 w / w% or more, about 20 w / w ./mass.% or more, about 25 wt./ w / w% or more, about 30 w / w% or more, about 35 w / w% or more, about 40 w / w% or more, about 45 w / w% or more , about 50 w / w% or more, about 60 w / w% or more, or about 70 w / w% or more. Tablets obtained after loading a loadable tablet with a pharmaceutically acceptable liquid composition generally meet the requirements of the pharmacopoeia. Thus, a tablet according to the invention typically has a hardness of at least about 20 N and / or a friability of at most about 5%, such as, for example, at most about 4%, at most about 3%, at most about 2%, at most about 1% or at most about 0.5%.In addition, it is believed that loading liquid into a loading tablet of the invention results in a substantially homogeneous distribution of liquid within the tablet. In addition, tablets can be designed to release the active substance substantially immediately or in a modified manner. A tablet designed for immediate release typically has a disintegration time of at most 15 minutes, according to Ph. Eur, whereas a film-coated tablet may have a disintegration time of at most about 30 minutes.For modified release tablets, the release of the active substance is important. In a typical tablet according to the invention, at least 75% of the therapeutically, prophylactic and / or diagnostically active substance is released after 30 minutes when tested by the dissolution method according to USP. As indicated above, a preferred embodiment is a tablet loaded with one or more therapeutically, prophylactically and / or diagnostically active substances. Principle of Tablet Effusion Disintegration The present inventors have found that disintegration of tablets loaded with a lipiphilic composition is not improved by the addition of a hydrophilic superdisintegrant due to the reduced swelling properties of the disintegrant in a lipid environment.In this case, you can apply another principle of disintegration based on the effect of boiling. Tablet disintegration is enhanced by internal release of carbon dioxide. The effervescence of the tablet formulation is based on the combination of metal carbonates with an acid source. The metal carbonates are carbonates such as sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, calcium carbonate and sodium sesquicarbonate. Sources of acids include citric acid, sodium dihydrogen citrate, disodium hydrogen citrate, tartaric acid, malic acid, fumaric acid, sodium dihydrogen phosphate, and sodium hydrogen sulfite.An acidic component can be incorporated into a tablet when the effervescence effect is obtained in vivo when the tablet is dissolved in acidic gastric juice and reacted with a metal carbonate. Coating The tablet can be coated with a film coating such as immediate or modified release, enteric coating, modified release coating, protective coating, release coating, etc. Suitable coating materials are, for example, methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, acrylic polymers, ethyl cellulose, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methyl cellulose phthalate, polyvinyl alcohol, sodium carboxymethyl cellulose acetate, cellulose acetate, cellulose acetate , shellac, sucrose, titanium dioxide, carnauba wax, microcrystalline paraffin, zein.Plasticizers and other ingredients can be added to the coating material. The same or a different active substance can also be added to the coating material. Melt Coating The hydrophobic lipid surface of a loaded tablet according to the invention can prevent adhesion of a polymer coating applied in an aqueous or organic solvent. Alternatively, various lipophilic, meltable lipids, sprayed in molten form and curable to the tablet surface using conventional coating equipment, are suitably used in the melt to form the coating.Suitable-8 013632 for hot melt coating are substances such as polyglycolized glycerides (gelucir 50/02, gelucir 62/05, gelucir 53/10), polyglyceryl palmitostearate, glyceryl behenate (compritol 888 ATO), glyceryl stearate Precirol ATO 5), polyglycolized unsaturated glycerides (labrafil M 1944). Active substances In the present context, a therapeutically and / or prophylactically active substance includes any biologically and / or physiologically active substance that has an effect on an animal, such as, for example, a mammal like a human.The term includes drugs, hormones, genes or gene sequences, a substance including an antigen, proteins, peptides, nutritional components like, for example, vitamins, minerals, lipids and carbohydrates, and mixtures thereof. Thus, the term includes substances that are useful in the treatment and / or prevention of diseases or disorders affecting animals or humans, or in the regulation of any physiological state of an animal or human. The term also includes any biologically active substance that, when administered in an effective amount, has an effect on living cells or organisms.Examples of active substances suitable for use in the tablet according to the invention are, in principle, any active substance, such as, for example, without limitation, water-soluble and also more slightly soluble or insoluble active substances. Thus, examples of active substances suitable for use are, for example, antibacterial agents, antihistamines and decongestants and decongestants, anti-inflammatory agents, antiparasitic agents, antiviral agents, local anesthetics, antifungals, amoebicides or trichomonocidal agents, analgesics, anti-anxiety agents. conditions, anti-clotting agents, anti-arthritic agents, anti-asthma agents, anti-arthritic agents, anticoagulants, anticonvulsants, antidepressants, anti-diabetic agents, anti-glaucoma agents, antimalarial agents, antimicrobial agents, antineoplastic agents, anti-obesity agents, antipsychotic agents antitussives, drugs against autoimmune disorders, drugs against impotence, drugs against parkinsonism, drugs against Alzheimer’s disease, antipyretics, anticholinergics, p antiulcer drugs, appetite suppressants, beta-blockers, beta-2 agonists, beta-agonists, blood glucose lowering drugs, bronchodilators, drugs with an effect on the central nervous system, cardiovascular drugs, cognitive enhancers, contraceptives , cholesterol-lowering agents, cytostatics, diuretics, germicides, H-2-blockers, hormonal agents, hypnotics, inotropic agents, muscle relaxants, muscle contraction agents, antidepressants, sedatives, sympathomimetics, vasodilators, vasoconstrictor factors, tranquilizers, electrolyte supplements, vitamins, anti-irritants, stimulants, anti-hormones, drug antagonists, lipid-regulating agents, uric acid excretion agents, cardiac glycosides, expectorants, laxatives, contrast agents, radiopharmaceuticals, imaging agents, etc. peptides, enzymes, growth factors, etc.e. Specific examples include, for example, anti-inflammatory drugs like, for example, ibuprofen, indomethacin, naproxen, nalofin; anti-parkinsonism agents like, for example, bromocriptine, biperidine, benzhexole, benztropine, etc .; antidepressants like, for example, imipramine, nortriptyline, pritiptyline, etc .; antibiotics like, for example, clindamycin, erythromycin, fusidic acid, gentamycin, mupirocin, amphomycin, neomycin, metronidazole, sulfamethisole, bacitracin, framycetin, polymyxin B, acitromycin, etc.etc .; antifungal agents like, for example, miconazole, ketoconazole, clotrimazole, amphotericin B, nystatin, mepyramine, econazole, fluconazole, flucytocin, griseofulvin, bifonazole, amorophine, mycostine T. antimicrobial agents like, for example, metronidazole, tetracyclines, oxytetracycline, penicillins, etc .; antiemetics like, for example, metoclopramide, droperidol, haloperidol, promethazine, etc .; antihistamines like, for example, chlorpheniramine, terfenadine, triprolidine, etc.d; anti-migraine agents like, for example, dihydroergotamine, ergotamine, pizophylline, etc .; coronary, cerebral or peripheral vasodilators like, for example, nifedipine, diltiazem, etc .; antianginal agents such as, for example, glyceryl nitrate, isosorbide dinitrate, molsidomine, verapamil, etc .; – 9 013632 calcium channel blockers such as, for example, verapamil, nifedipine, diltiazem, nicardipine, etc .; hormonal agents like, for example, estradiol, estrone, estriol, polyestradiol, polyestriol, dienestrol, diethylstilbestrol, progesterone, dihydroprogesterone, cyprosterone, danazol, testosterone, etc.etc .; contraceptives like, for example, ethinyl estradiol, linestrenol, ethynodiol, norethisterone, mestranol, norgestrel, levonorgestrel, deodestrel, medroxyprogesterone, etc .; antithrombotic agents like, for example, heparin, warfarin, etc .; diuretics like, for example, hydrochlorothiazide, flunarizine, minoxidil, etc .; antihypertensive agents like, for example, propanolol, metoprolol, clonidine, pindolol, etc .; corticosteroids like, for example, beclomethasone, betamethasone, betamethasone-17-valerate, betamethasone-dipropionate, clobetasol, clobetasol-17-butyrate, clobetasol-propionate, desonide, deoxymethasone, dexamethasone-lumetazluone-difluuone , hydrocortisone, hydrocortisone-17-butyrate, hydrocortisone butepratu, methylprednisolone, triamcinolone acetonide, gatsinonidu, Fluprednidene acetate, alklometazondipropionatu, fluocortolone, fluticasone propionate, mometasone Furat, desoximetasone, diflurazon-diacetate, galhinolu, clioquinol, chlorquinaldol, fluocinolone-acetonide and T.etc .; dermatological agents like, for example, nitrofurantoin, dithranol, clioquinol, hydroxyquinoline, isotretionine, methoxalene, methotrexate, tretionine, trioxalene, salicylic acid, penicillamine, etc .; steroids such as, for example, estradiol, progesterone, norethindrone, levonorgestrel, ethynodiol, levonorgestrol, norgestimate, gestanin, desogestrel, desogestrel 3-ketone, demegestone, promethoestrol, tesolnierone and efiron; nitro compounds like, for example, amyl nitrates, nitroglycerin and isosorbide nitrate, etc.etc .; opioids like, for example, morphine, buprenorphine, oxymorphone, hydromorphone, codeine, tramadol, etc .; prostaglandins such as, for example, a member of the PGA, PGB, PGE or PGF series, such as, for example, minoprostol, dinoprostone, carboprost, eneprostil, etc .; peptides like, for example, growth hormone releasing factors, growth factors (e.g. epidermal growth factor (EGF), nerve growth factor (NGF), TGF, PDGF, insulin growth factor (IGF), fibroblast growth factor (aFGF, bFGF and T.somatostatin, calcitonin, insulin, vasopressin, interferons, IL-2, etc., urokinase, serratiopeptidase, superoxide dismutase, thyrotropin-releasing hormone, hormone releasing luteinizing hormone (LHRH), hormone-releasing hormone hormone growth hormone releasing hormone (GHRH), oxytocin, erythropoietin (EPO), colon stimulating factor (CSF), etc. Other active substances of interest include ubiquinone (coenzyme Q10), omega-3 fatty acids including fish oils containing such fatty acids, statins including simvastatin, lovastatin, atorvastatin, pravastatin, fluvastatin, rosuvastatin, etc.d., fenofibrate. Prescription drugs like the following are also of interest: Cardiovascular drugs Zocor, Lipitor, Prevachol, Mevalotin, Mevacor, Lescol, Tricor, Norvasc, Cozaar and Gizaar, Prinvil and Prinzid, Diovan / Codiovan, Zestril, Vaseotech and Vaseretic, lotensin / sibatsen and lotrel, adalat, toprol-XL / seloken, tritace / delix, akupril and akuretik, avapro and avalid, lendil, monopril, blopress, atakand, tenormin, avapro / aprovel, coreg, altace, kapoten, plavix, lovenox / clexane, fraxiparin, reopro, panaldin, cordaron.Medicines for the central nervous system Paxil / Seroxat, Zolotoft, Prozac, Prozac Wikli and Sarafem, Effexor, Wellbutrin, Celexa, Remeron, Serzon, Ciprexa, Risperdal, Seroquel, Clozaril / Leponex, Neurontin, Depaktok, Lamictol, Imaxit, Tegrets / imigran, zomig, maxalt, ambien, stilnox, ultan / sevoran, diprivan, buspar, xanax, aricept, memantine, adderall, dystonia, botox. Antibacterial agents Augmentin, tsipro / tsiprobay, zitromax, biaxin, levaquin and floxin, rocefin, primaxin, ceftin / cinnat, kravit, zosin / tazocin, cefzil, tekvin, tortaz / fortum, kombivir, cerit, valxivanx, epix, epix, Viracept, Viramune, Kaletra, Diflucan, Lamisil, Sporanox.- 10013632 Respiratory medicines Claritinallegra, Telfast, Zyrtec, Flonase / Flixonase, Atrovent, Nasonex, Rinocort, Alezion, Singulair, Flovent / Flixotide, Advair / Seretide, Serevent, Pulmikort, Ventolin, Combivent, Sinevosin Gastrointestinal Medicines Prilosek / Lozek, Prevacid, Gaster, Takepron, Zantac, Pantosol, Nexium, Protonix, Acifex / Pariet, Pepsid, Axid, Zoton, Zofran. Anticancer drugs Taxol, Taxotere, Nolvadex, Herceptin, Ellenz / Pharmorubicin, Lupron, Zoladex, Leuplin, Kazodex, Intron A, Peg-Intron and Rebertron, Rituxan, Gemzar, Paraplatin, Camptosar.Antiarthritic drugs / analgesics Celebrex, Viox, Enbrel, Remicade, Voltaren, Mobic, Duragesic, Ultram and Ultracet. Means for the treatment of blood diseases Procrit / Eprex, Epogen, Epogin, Neorecormone, Neupogen, Novoseven. Medicines for diabetes Glucophag, Humulin Avandia, Humalog, Actos, Amaryl, Glucovans, Glucophage XR, Glucotrol XL, Precose / Glucobay. Regulators of bone metabolism Fozamax, Evista, Miacalcin, Acton, Aredia. Means for the treatment of urinary disorders Harnal, proscar, cardura, flomax, detrol.Hormones Premarin, premphase and prempro, estraderm, synthroid. Immunosuppressive drugs Neoral / Sandimmune, Celsept, Rapamun, Tacrolimus, eg Prograf, Medrol. Medicines for the treatment of multiple sclerosis Avonex, Betaseron / Betaferon, Rebif, Copaxone. Biological agents Prevnar, Engerix-B, Infanrix, Gamimun N. Medicines for sexual dysfunction Viagra. Means for obtaining images Iopamiron, omnipack, magnevist. Ophthalmic medicines Xalatan, Trusopt and Cosopt.Dermatological medicines Accutane / Roaccutane, Cleocin. Therapeutic agents for growth disorders Genotropin, humatrope. Medicines for infertility Gonal-F, folistim (puregon) Medicines for Gaucher’s disease Cerezyme. Medicines for obesity Xenical. Medicines for acromegaly Sandostatin. Depo-Provera contraceptives. Other interesting examples of active substances, which are slightly soluble, slightly soluble or insoluble in water, are indicated in the following tables: – 11013632 Table 1.Poorly soluble drug candidates – 14013632 Table 2. Poorly soluble drugs with low bioavailability The amount of active ingredient included in the tablet can be selected according to known pharmaceutical formulation principles. In general, the dose of active substance present in a tablet according to the invention depends, inter alia, on the particular drug substance, the age and condition of the patient, and the disease being treated. In a specific embodiment, the therapeutically, prophylactically and / or diagnostically active substance is solid at ambient temperature.However, this is not an absolute requirement, it can also be liquid at room temperature. The active agent may also be present in the form of a dispersion of the active agent in a pharmaceutically acceptable liquid composition, or the active agent may be present in the form of an emulsion, including an SMEDD (self-emulsifying drug delivery system). As indicated above, the active agent can be dispersed in a pharmaceutically acceptable liquid composition. In a specific embodiment, the active agent is at least partially dissolved in a pharmaceutically acceptable liquid composition and / or it is at least partially present in amorphous form.Other aspects of the invention The invention also relates to a process for the preparation of a tablet comprising the following steps: i) preparation of a loadable tablet as defined in any one of claims 1 to 32, optionally comprising one or more therapeutically, prophylactically and / or diagnostically active substances ii) loading the loading tablet obtained from step i) with a pharmaceutically acceptable liquid 15013632 composition as indicated in any of claims 33-59, optionally including one or more therapeutically, prophylactically and / or diagnostically active substances, for a period of time that is sufficient to saturate the loadable tablet with a pharmaceutically acceptable liquid composition.Loading a loading tablet with a pharmaceutically acceptable liquid composition, optionally including one or more therapeutically, prophylactically and / or diagnostically active substances, is usually carried out by spraying, or it is carried out by placing a loading tablet in an excess of a pharmaceutically acceptable liquid composition, optionally including one or more therapeutically, prophylactically and / or diagnostically active substances. In the above method, the time period in step ii) is usually at most about 60 minutes, such as, for example, at most 45 minutes, or at most 30 minutes, for the number of tablets loaded corresponding to 1 kg (and corresponding time periods for batches having other than 1 kg, mass).The invention is further illustrated by the following non-limiting examples. EXAMPLES Example 1 Preparation of Chargeable Tablets and Their Properties Six tablet formulations were made from materials for the absorption of Airperl 300 oil (silicon dioxide, Degussa), neusilin US2 (magnesium aluminum metasilicate, Fuji Chemical Magnesium stearate was mixed with the rest of the components in a Turbula mixer in for 3 minutes The tablets were compressed on a Diaf TM20 single die tabletting machine Tablet size: 9 mm round compound conical tablet.The tablets were placed in corn oil for 24 hours. Oil absorption was complete within the first hour. Tablets of composition 5 were loaded with Imvitor 308, sasol (glyceryl monocaprylate) with 10% dissolved simvastatin. The oil loading was carried out at a temperature above the melting point of imitator 308 (mp 35 ° C), corresponding to 40 ° C – 16013632 Composition 1 Table 1. The ability to absorb oil in tablets containing neusilin US2 (composition 1) Tablet hardness was determined by a Schleuninger tablet hardness tester 8M.Table 2. Hardness of tablets before and after loading with oil (composition 1) The disintegration time did not exceed 24 hours before and after loading with oil. The disintegration time was reduced to less than 15 minutes by the addition of Ac-di-sol at a concentration of 1% (before loading) and decreased to 5 hours after loading. Ac-di-sol (croscarmellose sodium salt, FMC) is a superdisintegration agent that does not interfere with the oil absorption capacity of neusilin. The porosity of the tablets before loading is calculated based on the tablet density t and the true density s of the ingredients.The porosity of the tablet is calculated according to Equation 1. The density of the tablet is based on the ratio between the weight and volume of the tablet. The true density of the ingredients is based on the gas pycnometric density determined in helium using Micromeritics Accupyc 1330. The maximum corn oil loading capacity on a weight basis is calculated according to Equation 2. Density of corn oil, 1 = 0.92 g / cm 3. Table 3. Usage oil loading capacity (composition 1) – 17013632 composition 2.Table 4. Oil absorption capacity of Avicel tablets (Formulation 2) The hardness of the tablets was determined with a Schleuninger 8M tablet hardness tester. Table 5. Hardness of tablets before and after loading with oil (composition 2) Table 6. Use of oil loading capacity (composition 2) Composition 3. Table 7. Ability to absorb oil by tablets with a mixture of AirPerl / PEG 6000 (composition 3) The hardness of the tablets was determined by a tester hardness of Schleuninger tablets 8M.Table 8. Hardness of tablets before and after loading with oil (composition 3) – 18013632 Table 9. Use of oil loading capacity (composition 3) Composition 4. Table 10. Ability to absorb oil by tablets with a mixture of AirPerl / Avicel (composition 4) Table 11. Hardness Tablets before and after loading with oil (Formulation 4) Table 12. Time of tablet disintegration before and after loading with oil (Formulation 4) Compared to Formulation 3, tabletting properties and tablet hardness were improved by adding Avicel PH 101 instead of PEG 6000.- 1

32 Composition 5. Table 13. The ability to absorb oil in tablets with Avicel loaded with 10% simvastatin solution in imvitor 308 (composition 5) Table 14. Hardness of tablets before and after loading with 10% simvastatin solution in imvitor 308 Table 15. Time of tablet disintegration before and after loading with oil (composition 5) Composition 6 Table 17: Oil absorption capacity of the tablets with fujicalin loaded with corn oil (composition 6) – 20013632 Table 18. Hardness of the tablets before and after loading with corn oil (composition 6) Table 19.Tablet disintegration time before and after loading with corn oil (Formulation 6) liquid form or dissolved or dispersed in a liquid carrier. Oils can be applied to tablets using conventional coating techniques (drums, perforated vessels, or fluidized bed).The oil flow rate must be adjusted to balance the rate of oil absorption into the tablet cores. The oil absorption capacity is determined by the porosity of the tablet core. The oil fills the pores of the tablets close to saturation. Any substance that provides tablets with a porosity in the range of 30-90% is acceptable. As the substance for the core of the tablets, substances other than those mentioned above can be used, such as calcium carbonate, magnesium oxide, preferably spray-dried substances with satisfactory flowability and high specific surface area.The disintegration time of the tablets can be controlled by the addition of conventional tablet disintegrants, and these disintegrants are used in immediate release tablet formulations as well as controlled release matrix tablets. Examples of porous tablets loaded with active substances (API) Example 2 Description of tablets with a core Tablet diameter: 8 mm (compound conical tablet). The tablets were compressed on a Diaf TM20 single die tabletting machine. Description of the Loaded Tablet (1 mg Tacrolimus) 0.95% tacrolimus is dissolved in polyethylene glycol 400 and sprayed onto a Neusilin US2-cored tablet at ambient temperature in a coating vessel.The composition of the loaded 1 mg tablet is shown in table. 1 corresponding to a loaded tablet weight of 200 mg, corresponding to a filler loading of 53% w / w. Average tablet hardness: 52 N. Table 20. Tablet composition with 1 mg tacrolimus loaded with tacrolimus solution in PEG 400 Tablet diameter: 10 mm (compound conical tablet). The tablets were compressed on a Diaf TM20 single die tabletting machine. Description of the Loaded Tablet (20 mg Atorvastatin) Atorvastatin 10% is dissolved in molten Imitator 308 (glyceryl monocaprylate) at 40 ° C and the solution is sprayed onto the US2 neusilin core tablet heated to 35 ° C in a coating vessel.The loaded tablets, after loading, are cooled in a refrigerator 21013632 to cure the filler. The composition of the tablet with a loading of 20 mg is shown in table. 2 corresponding to a tablet loaded weight of 400 mg, corresponding to a filler loading of 50 w / w%. Average tablet hardness: 48 N. Table 21. Tablet formulation with 20 mg of atorvastatin loaded with a solution of atorvastatin in glyceryl monocaprylate Tablets were compressed on a Diaf TM20 single die tableting machine. Description of the loaded tablet (145 mg of fenofibrate) Fenofibrate at a concentration of 35% is dissolved in a molten mixture of polyethylene glycol 6000 and poloxamer 188 (70:30) at a temperature of 80 ° C and the solution is sprayed onto a tablet with a US2 neusilin core heated in a coating vessel to a temperature 70 S.After loading, the tablets are cooled in a coating vessel to a temperature below the melting point (60 ° C) of PEG and Poloxamer. The composition of the loaded 145 mg fenofibrate tablet is shown in table. 3 corresponding to a loaded tablet weight of 767 mg, corresponding to a filler loading of 54% w / w. Average tablet hardness: 57 N. Table 22. Tablet composition with 145 mg of fenofibrate loaded with a solution of fenofibrate in a molten mixture of PEG 6000 and poloxamer 188 (70:30) Tablet diameter: 7 mm (compound conical tablet).The tablets were compressed on a Diaf TM20 single die tabletting machine. Description of Loaded Tablet (10 mg Simvastatin) Simvastatin 10% was dissolved in (MCT) viscoleo on a US2 neusilin core in a coating vessel. The composition of the loaded 10 mg simvastatin tablet is shown in table. 4 corresponding to a loaded tablet weight of 185 mg, corresponding to a filler loading of 54% w / w. Table 23. Composition of a tablet with 10 mg of simvastatin loaded with a solution of simvastatin in viscoleo-22013632 Example 6.Loading of tablets from neusilin viscoleo (medium chain glyceride) Tabletting method Neusilin tablets were compressed on a Diaf TM 20 single die tabletting machine. Tablet Properties Before Loading Loading Method (Loading Method) 50 g tablets were loaded with viscoleo into a laboratory scale fluidized bed Phast FB 100 using a top nozzle spray coating unit. Tablet Properties After Loading: Conclusion Conventional fluid bed coating equipment is convenient for loading a liquid composition onto porous tablets within a short processing time.The tablets quickly absorb liquid when sprayed onto the surface of the tablet. Tablet hardness is not affected by liquid loading. The spread in mass increases from 1.6 to 5.2%, however, remaining within acceptable limits relative to the spread of doses when the active substance is turned on. FORMULA OF THE INVENTION 1. A downloadable tablet having a porosity of 30 v / v% or more for use as a pharmaceutical carrier composition for a pharmaceutically acceptable liquid composition comprising at least 50 wt./ wt% pharmaceutically acceptable porosity-providing excipients selected from metal silicates and having a hardness of at least 20 N. of these, tablets together with at most 50 w / w% lactose provide a tablet which has a porosity of 30 vol% or more. 3. Loaded tablet according to claim 2, where one or more porosity-providing excipients are present in the tablet at a concentration of about 50 wt./mas.% or more. 4. A chargeable tablet according to claim 3, wherein the one or more porosity-providing excipients provide a tablet that has a porosity of 30 vol% or more and is present in the tablet at a concentration of about 60 w / w% or more, such as, for example, about 70 w / w% or more, about 80 w / w% or more, about 90 w / w% or more, or about 95 w / w% or more. 5. Downloadable tablet according to any one of paragraphs.2-4, wherein one or more porosity-providing excipients provide a tablet that has a porosity of 30 vol% or greater and has a specific surface area (BET surface area) of at least 50 m 2 / g as measured by gas adsorption. 6. A loadable tablet according to any one of the preceding claims, wherein the tablet, when placed in corn oil for 24 hours, has a tablet loading of at least 20 w / w%, such as, for example, at least 25 w / w. % or at least 30 wt./ wt% corn oil (based on the total weight of the solid dosage form after loading). 7. A chargeable tablet according to any one of the preceding claims, wherein the tablet has a hardness of about 35 N or more, about 40 N or more, about 45 N or more, or about 50 N or more. 8. A loadable tablet according to any one of the preceding claims, which has a friability of about 5% or less, such as, for example, about 4% or less, about 3% or 23,013,632 less, about 2% or less, about 1% or less.9. A loading tablet according to any one of claims 2 to 8, wherein the pharmaceutically acceptable excipient is a metal silicate selected from the group consisting of sodium silicate, potassium silicate, magnesium silicate, calcium silicate including synthetic calcium silicate, zinc silicate, silicate aluminum, sodium aluminosilicate, magnesium aluminum silicate, magnesium aluminum metasilicate, aluminum metasilicate, neusilin SG2, neusilin US2 and mixtures thereof. 10. A chargeable tablet according to any one of claims 2 to 9, wherein the metal silicate is a swellable smectite-type clay selected from the group consisting of bentonite, vegum and laponite.11. A chargeable tablet according to any one of claims 2 to 10, wherein the metal silicate is selected from alkaline earth metal silicates and aluminum silicates including magnesium aluminum metasilicate. 12. A chargeable tablet according to any one of claims 9 to 11, wherein the metal silicate is neusilin. 13. A loadable tablet according to any of the preceding claims, which is therapeutically inert. 14. A chargeable tablet according to claim 13, comprising one or more inert pharmaceutically acceptable excipients. 15. A tablet as defined in any one of paragraphs.1-14 loaded with a pharmaceutically acceptable liquid composition at a concentration of about 20 w / w% or more, such as, for example, about 25 w / w% or more, or about 30 w / w% or more (in based on the total weight of the solid dosage form after loading). 16. The tablet of claim 15, wherein the pharmaceutically acceptable liquid composition is present at a concentration of about 40 w / w% or more, such as, for example, about 50 w / w% or more, or about 60 w / w% or more./ wt% or more (based on the total weight of the solid dosage form after loading). 17. A tablet according to claim 15 or 16, wherein the pharmaceutically acceptable liquid composition has a viscosity of at most about 600 mPa / s at a temperature of at most about 150 C. 18. A tablet according to any one of claims 15 to 17, wherein the pharmaceutically acceptable liquid composition has a melting point of at least about 0 C and at most about 250 C. 19. The tablet of claim 18, wherein the pharmaceutically acceptable liquid composition has a melting point of about 5 C or more, such as, for example, about 10 C or more, about 15 C or more, about 20 C or more, or about 25 C or more.20. A tablet according to any one of claims 15-19, wherein the pharmaceutically acceptable liquid composition comprises an oil or oil-like substance. 21. A tablet according to any one of claims 15-20, wherein the pharmaceutically acceptable liquid composition comprises a pharmaceutically acceptable solvent. 22. A tablet according to claim 20, wherein the oil or oily substance is selected from the group consisting of vegetable oils, hydrogenated vegetable oils, and animal oils. 23. A tablet according to claim 22, wherein the oil or oil-like substance is selected from the group consisting of apricot oil, almond oil, avocado oil, castor oil, coconut oil, cocoa butter, corn oil, cottonseed oil, grape oil, jojoba oil, linseed oil, maize oil, olive oil, palm oil, peanut oil, peach oil, poppy seed oil, canola oil, sesame oil, soybean oil, sunflower oil, artichoke seed oil, walnut oil, wheat germ oil, beef tallow, lard, tall oil, whale oil and mixtures thereof.24. A tablet according to claim 22, wherein the oil or oil-like substance is a hydrophilic oil or an oil-like substance selected from the group consisting of polyether glycols such as, for example, polyethylene glycols, polypropylene glycols; polyoxyethylene; polyoxypropylene; poloxamers and mixtures thereof, or it can be selected from the group consisting of xylitol, sorbitol, sodium potassium tartrate, sucrose tribgenate, glucose, rhamnose, lactitol, behenic acid, hydroquinone monomethyl ester, sodium acetate, ethyl fumarate, myristic acid, citric acid , gelucir 50/13, other types of gelucir such as, for example, gelucir 44/14, etc.d., gelucir 50/10, gelucir 62/05, sucroester 7, sucroester 11, sucroester 15, maltose, mannitol and mixtures thereof. 25. A tablet according to claim 22, wherein the oil or oily substance is a hydrophobic oil or oily substance selected from the group consisting of saturated straight chain hydrocarbons, sorbitan esters, paraffins; fats and oils such as, for example, cocoa butter, beef tallow, lard, polyethylene glycol esters; higher fatty acids such as, for example, stearic acid, myristic acid, palmitic acid, higher alcohols such as, for example, cetanol, stearyl alcohol, low melting waxes, such as, for example, glyceryl monostearate, glyceryl monooleate, hydrogenated tall oil, myristyl alcohol, stearyl alcohol, substituted and / or unsubstituted monoglycerides, substituted and / or unsubstituted – 24013632 diglycerides, substituted and / or unsubstituted triglycerides, yellow beeswax, white beeswax, carnauba wax, castor wax, monoacetyl wax, Japanese wax; NVP polymers, PVP polymers, acrylic polymers or mixtures thereof.26. The tablet of claim 22, wherein the oil or oil-like substance is polyethylene glycol having an average molecular weight in the range from about 400 to about 35,000, such as, for example, from about 800 to about 35,000, from about 1,000 to about 35,000, such as e.g. polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 3000, polyethylene glycol 4000, polyethylene glycol 5000, polyethylene glycol 6000, polyethylene glycol 7000, polyethylene glycol 8000, polyethylene glycol 9000, polyethylene glycol 10000, polyethylene glycol 15000, polyethylene glycol 20,000 or polyethylene glycol.In some cases, polyethylene glycol with a molecular weight of from about 35,000 to about 100,000 can be used. 27. The tablet of claim 22, wherein the oil or oil-like substance is polyethylene oxide having a molecular weight of from about 2,000 to about 7,000,000, such as, for example, from about 2,000 to about 100,000, from about 5,000 to about 75,000, from about 10,000 to about 60,000, from about 15,000 to about 50,000, from about 20,000 to about 40,000, from about 100,000 to about 7,000,000, such as, for example, from about 100,000 to about 1,000,000 , from about 100,000 to about 600,000, from about 100,000 to about 400,000, or from about 100,000 to about 300,000.28. A tablet according to claim 22, wherein the oil or oil-like substance is a poloxamer, such as, for example, poloxamer 188, poloxamer 237, poloxamer 338 or poloxamer 407, or other block copolymers of ethylene oxide and propylene oxide, such as the Pluronic and / or tetronic series, where suitable block copolymers of the Pluronic series include polymers having a molecular weight of about 3000 or greater, such as, for example, from about 4000 to about 20,000, and / or a viscosity (Brookfield) from about 200 to about 4000 cps, such as, for example, from about 250 to about 3000 cps, where suitable examples include Pluronic F38, P 65, P68LF, P 75, F77, P 84, P 85, F87, F88, F98, P 103, P 104, P 105, F108, P 123, F123, F127, 10R8, 17R8, 25R5, 25R8, etc.where suitable block copolymers of the Tetronic series include polymers having a molecular weight of about 8000 or greater, such as, for example, about 9000 to about 35000, and / or a Brookfield viscosity of about 500 to about 45000 cps , such as, for example, from about 600 to about 40,000 cps, with the viscosities given above being determined at 60 ° C for substances that are pastes at room temperature and at 77 ° C for substances that are solid at room temperature.29. A tablet according to claim 22, wherein the oil or oil-like substance is a sorbitan ester, such as, for example, sorbitan diisostearate, sorbitan dioleate, sorbitan monolaurate, sorbitan monoisostearate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sosvioleate, sorbitan sosquioleate sorbitan sesquistearate, sorbitan triisostearate, sorbitan trioleate, sorbitan tristearate, or mixtures thereof. 30. A tablet according to claim 22, wherein the oil or oil-like substance is a mixture of various oils or oil-like substances, such as, for example, a mixture of hydrophilic and / or hydrophobic substances.31. A tablet according to claim 22, wherein the oil or oil-like substance is a solvent or semi-solid excipient like, for example, propylene glycol, polyglycolized glycerides, including gelucir 44/14, a complex of vegetable fatty substances including cocoa butter, carnauba wax, vegetable oils like, for example, almond oil, coconut oil, corn oil, cottonseed oil, sesame oil, soybean oil, olive oil, castor oil, palm oil, peanut oil, rapeseed oil, grape oil, etc.hydrogenated vegetable oils such as, for example, hydrogenated peanut oil, hydrogenated palm oil, hydrogenated cottonseed oil, hydrogenated soybean oil, hydrogenated castor oil, hydrogenated coconut oil; natural fatty substances of animal origin, including beeswax, lanolin, fatty alcohols, including cetyl, stearyl, lauric, myristic, palmitic, stearic fatty alcohols; esters including glycerol stearate, glycol stearate, ethyl oleate, isopropyl myristate; liquid transesterified semisynthetic glycerides, including miglycol 810/812; amide or alkanolamides of fatty acids, including ethanol stearamide, diethanolamide of fatty acids of coconut oil, esters of acetic acid and mono- and diglycerides, esters of citric acid and mono- and diglycerides, esters of lactic acid and mono- and diglycerides, mono- and di-glycerides, polyglycerides , polyglycerol polyricinoleate, propylene glycol and fatty acid esters, sorbitan monostearates, sorbitan tristearates, sodium stearoyl lactylates, calcium stearoyl lactylates, diacetyl tartaric acid esters and mono- and diglycerides, etc.25013632 32. A tablet according to any one of claims 15 to 31, wherein the pharmaceutically acceptable liquid composition is a dispersion, including an emulsion, a microemulsion, such as a self-microemulsifying drug delivery system (SMEDDS), or a suspension. 33. A tablet according to any one of claims 15 to 32, wherein the concentration of the pharmaceutically acceptable liquid composition in the tablet is about 5 w / w% or more, such as, for example, about 10 w / w% or more, about 15 w / w% or more, about 20 w / w% or more, about 25 w / w% or more, about 30 w / w% or more, about 35 w / w% or more, about 40 w / w% or more, about 45 w / w% or more, about 50 w / w% or more, about 60 w / w% or more, or about 70 w / w% or more. 34. A tablet according to any one of claims 15 to 33, further comprising one or more therapeutically, prophylactically and / or diagnostically active substances.35. A tablet according to claim 34, wherein the active agent is dispersed in a pharmaceutically acceptable liquid composition. 36. A tablet according to claim 34, wherein the active agent is at least partially dissolved in a pharmaceutically acceptable liquid composition. 37. A tablet according to claim 34, wherein the active agent is at least partially present in amorphous form. 38. A tablet according to any one of claims 15 to 37 having a hardness of at least about 25 N. 39. A tablet according to any of claims 15 to 38 in the form of tablets having a friability of at most about 5%, such as, for example, at most more about 4%, at most about 3%, at most about 2%, at most about 1%, or at most about 0.5%.40. Tablet according to any one of claims 15 to 39, having a disintegration time of at most 15 minutes, according to the test methods according to Ph. Eur. 41. A tablet according to any one of claims 34-40, wherein at least 75% of the therapeutically, prophylactic and / or diagnostically active substance is released after 30 minutes when tested by the dissolution method according to USP. 42. A method for preparing a tablet, comprising the following steps: i) obtaining a loadable tablet as defined in any one of claims 1 to 14, optionally including one or more therapeutically, prophylactically and / or diagnostically active substances, ii) loading a loadable tablet obtained from stage i), a pharmaceutically acceptable liquid composition as defined in any one of paragraphs.15-41, optionally including one or more therapeutically, prophylactically and / or diagnostically active substances, for a period of time that is sufficient to saturate the loading tablet with a pharmaceutically acceptable liquid composition. 43. The method of claim 42, wherein loading the loadable tablet with a pharmaceutically acceptable liquid composition, optionally including one or more therapeutically, prophylactically and / or diagnostically active substances, is carried out by spraying.44. The method of claim 42, wherein loading the loading tablet with a pharmaceutically acceptable liquid composition, optionally including one or more therapeutically, prophylactically and / or diagnostically active substances, is performed by placing the loading tablet in an excess of a pharmaceutically acceptable liquid composition, optionally including one or several therapeutically, prophylactically and / or diagnostically active substances. 45. The method according to any one of claims 42 to 44, wherein the time period in step ii) is at most about 60 minutes, such as, for example, at most about 45 minutes, or at most about 30 minutes for a tablet loading amount corresponding to 1 kg .